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ABSTRACT

ALLOSTERIC REGULATION OF DENGUE VIRUS TYPE-2 PROTEASE
FEBRUARY 2014
MUSLUM YILDIZ, B.S., UNIVERSITY OF EGE
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Jeanne A. Hardy
Dengue Fever is a global problem with a worldwide effectiveness that put 2.5 Billion people
under the risk, infect 50 million people and causes 30000-50000 people death each year. DHF
was first recognized in the 1950s during the dengue epidemics in the Philippines and Thailand.
By 1970 nine countries had experienced epidemic DHF and now, the number has increased more
than fourfold and continues to rise. Today emerging DHF cases are causing increased dengue
epidemics in the Americas, and in Asia, where all four dengue viruses are endemic. Vaccine
development against Dengue Virus has been impossible to date, due to effective vaccination to
prevent DHF will require a tetravalent vaccine, because epidemiologic studies have shown that
preexisting heterotypic dengue antibody is a risk factor for DHF a lethal form of dengue fever.
To date there are no pharmaceutical treatments for Dengue fever. DV proteome is composed of 8
proteins and dengue virus protease is one of them and it is essential for virus replication therefore
it has being a potential drug target for dengue fever treatment. Active-site inhibitors of proteases
have been successfully used to treat other virally transmitted diseases of global importance such
as HIV and Hepatitis C, however protease active site inhibitors they are subject to development
of resistance. In addition, it is often difficult to target the active site due to overlapping sequence
preference with endogenous human proteases. This overlap in specificity of active-site inhibitors
contributes to unwanted side effects.
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A principal bottleneck is that traditional drugs are designed to bind to one protein and control the
function of only that protein at the active (primary functional) site. Unfortunately, similar active sites are
almost always present in related proteins, leading to lack of drug specificity and thus to many unwanted
side effects. A promising alternative is to use allosteric sites. Allosteric sites are cryptic drug binding
sites that are spatially distinct from the active site. They allow the protein to be locked into a unique
conformation that either turns the protein ‘on’ or ‘off’. Historically it has been difficult or impossible to
find allosteric sites, because mechanisms of allostery were poorly understood and tools for their
identification were lacking. Our unique combination of experimental approaches has enabled us to
identify new allosteric sites and new allosteric mechanisms of control in four different biomedically
important proteins. Many proteins have multiple allosteric sites. Allosteric sites can often be exploited
for much more specificity than active sites. We have developed and implemented a technology for
discovering new allosteric sites in proteases and have applied this to NS2B-NS3pro from dengue virus
type 2. In this thesis we report an allosteric site in NS2B-NS3pro that can be targeted in biomedical
studies. We also have shown that the internal flexibility of NS2B-NS3pro is critical for catalytic activity.
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CHAPTER 1
INTRODUCTION
1.1 Dengue Fever
The mosquito-born dengue virus causes dengue fever, which is an acute febrile
illness (1). The major symptoms are fever, headache, muscle and joint pain, nausea,
vomiting and a rash (2). The effects of dengue fever are significantly more severe in
children under age 15 years than in adults (3). Dengue fever is an ancient disease that
became worldwide health problem during the 18th and 19th centuries, during a time when
commerce dramatically expanded. During that era dengue virus spread along with
commercial ships trafficking goods between ports (4).
Dengue fever is now the most widespread (Fig. 1) and severe mosquito-born viral
disease in tropical regions (5, 6). According to the World Health Organization (WHO)
there are more than 100 million reported infections annually. WHO data have shown that
dengue fever is endemic in 100 countries, including in the Americas, where 890,000
cases of infection were reported in 2007 alone (www.who.int).

Figure 1. Countries in which dengue fever is endemic are shown in blue (Figure
reprinted from www.who.int).
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1.2 Dengue Hemorrhagic Fever (DHF)
DHF is the more severe and often lethal form of dengue fever (7-10). It can be
seen in all age groups and causes 30,000 and 50,000 death each year (11). Infection of a
second serotype, subsequent to a first bout of dengue fever, is known to be the main
reason of the disease severity (12, 13).
1.2.1 Dengue Hemorrhagic Fever Pathophysiology
DHF generally begins with and extremely high temperature fever. The
temperature is usually (38-40°C) and continues for 2-7 days (14). Following the high
fever, the main pathophysiological change that determines the severity of DHF is plasma
leakage (15). The plasma leakage phase that can be defined as increase in capillary
permeability leads to extravasation of fluid and haemoconcentration (16).
1.3 Dengue Virus Life Cycle
There are two major steps in transmission of dengue virus to humans. The first
step is distribution of dengue vector by the Aedes aegypti mosquito (Fig. 2 www.cdc.gov)
and the second step is cell infection by live dengue virus particles.

Figure 2. Circulation of dengue virus by Aedes aegypti mosquitos is shown (Figure
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reprinted from www.cdc.gov).
Dengue virus is transmitted to humans by Aedes aegypti mosquitos that are
carrying the dengue virus vector. After taking a blood meal, female Aedes aegypte
produce eggs that can survive for months. A female Aedes aegypti can produce up to
1000 eggs in her lifetime. The first step in the Aedes aegypti life cycle is submerging the
eggs in water. Eggs hatch in the aquatic habitat and form larvae (Fig. 2, picture 1) in 2-7
days. During the following 4 days, the larvae (Fig. 2, picture 2) will be able to grow from
the first to fourth instar stages. When a larva has obtained enough energy and has
progressed to the fourth instar, metamorphosis is started, changing the larva into a pupa
(Fig. 2, picture 3). Pupae do not feed; they just change in form until the body of the adult,
flying mosquito is formed. Then, the newly formed adult raise from the water after
breaking the pupal skin (Fig. 2, picture 4, inset). The entire life cycle usually ends after 810 days of growth at room temperature www.cdc.gov). These mature mosquitoes are then
capable of acquiring the virus from infected human and/or are they born with the virus
natively infecting them. Once an infected mosquito bites an uninfected human, the virus
can pass from the salvia of the mosquito to the human host.
Once inside the human host, the dengue virus life cycle proceeds at the molecular
level due to an interaction between the virus and clathrin receptors on the cell membrane
(Fig. 3) (17). Cell entry follows this interaction by clathrin-dependent receptor-mediated
endocytosis (18). This endocytic process results in fusion between the viral membrane
and the cellular membrane and leads to formation of endosomes that are taken into the
cells. A change in the intra-endosome pH triggers the viral genome release into the
cytoplasm of the cell (19, 20) resulting in infection of that cell.
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H. M. van der

Figure 3. Steps in cellular infection by dengue virus. Figure reprinted from [7].

The host-cell translation machinery is able to translate the ssRNA that encodes the
genetic information of the virus (21). This ssRNA produces a single polyprotein polymer
that consists of 8 components (Fig. 3A). The polyprotein is cleaved first by host cell
proteases which frees dengue virus protease. The free dengue virus protease (Fig. 3B) is
active and processes the rest of polyproteins to the individual proteins that then capable
of playing vital roles in viral life cycle (22). The polyprotein contains both structural and
non-structural proteins. The major structural proteins form the viral coat, where as the
nonstrluctural proteins have enzymatic functions such as protease (NS2B-NS3), helicase
(NS3), methyltransferase and RNA-dependent RNA polymerase (NS5).
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The other non-structural proteins such as NS1 and NS2 are known to be involved
in virus replication complex while NS4 is an integral membrane protein that has role in
induction of membrane alteration.

Figure 4. Dengue virus polyprotein composition. (A) The dengue virus polyprotein is
cleaved by a number of proteases as indicated to resulting in both structural (coat) and
non-strucutral proteins. The dengue virus protease recognition sites in dengue virus intact
polyprotein are indicated by filled black triangles. (B) Figure reprinted from (23).
1.3.1 Dengue Virus Structure
The coat proteins (structural proteins, Fig. 4) allow assembly of the viral particle.
The dengue virus coat is formed from 90 Envelope potein dimers using icosahedral
geometry to produce a viral particle with a diamater of 500Å. The viral surface has 60
spikes that are quasi-trimers of the envelope protein and uncleaved precursor membrane
(prM) proteins (24).
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Figure 5. Cryo-EM structure of dengue virus.(a) and dengue virus particles under the
high magnification of electron microscope (b). Figure reprinted from (25).Dengue virus
coat is formed from 90 Envelope potein E dimers using icosahedral geometry to produce
a viral particle with a diamater of 500Å. The viral surface has 60 spikes that are quasitrimers of E and uncleaved precursor membrane (prM) proteins. Figure reprinted from
(24).
1.4 Dengue Fever Treatment
A number of studies are focused on finding a cure for dengue fever. The studies have
taken two approaches: i) developing a vaccine against virus and ii) targeting the viral
system with a small molecule drug. Despite tremendous effort in the field there is no
approved treatment for dengue fever yet. Palliative care is standard for dengue fever and
dengue hemorrhagic fever. Fever reducers are simply used for dropping the high fevers of
patients who are diagnosed with dengue fever. Fluids are also supplied if dehydration is
observed.
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1.4.1 Vaccine Studies
Generically, a vaccine is an agent that increases immunity to a particular disease.
A typical vaccine contains a portion or the whole body of the disease-causing
microorganism. These agents are usually made from killed or attenuated forms of the
microorganism, surface proteins, genome contents or its toxins (Fig. 5).

Figure 6. Possible agents that may be used for vaccine development. Figure reprinted
(26).
The part of microorganism that is introduced to the body stimulates the immune
system that destroys microbe, and the immune systems remembers the microbial antigen.
Memory cells that are remained after vaccination stay ready to neutralize the foreign
reagent during second infection.
Due to the prevalence of dengue virus and the accompanying dengue fever,
vaccine development for dengue virus is an active area of research. Four dengue virus
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serotypes (DENV), DENV-1, -2, -3 and -4 cause the dengue fever disease (27). Each of
these serotypes can coexist in endemic areas (16, 28, 29). Infection by any one of the
serotypes is enough for life-long immunity against second infection by the same serotype,
but does not establish any protection against secondary infections by one of the other
three serotypes (5, 30). In fact, not only is the presence of antibodies from one serotype
ineffective against another serotype; they actually enhance the infectivity of other
serotype during second infection by a mechanism that called antibody dependent
enhancement (ADE, see below) (31-35). This means that patients often develop disease
symptoms subsequent to immunization with additional serotypes. This complication has
made dengue fever vaccines virtually impossible.
In order to make an effective, disease-free vaccine protocols, it is essential that
patients acquire immunity to all four serotypes simultaneously. Therefore dengue vaccine
development studies are aiming a tetravalent vaccine that will neutralize all four DENV
serotypes simultaneously. Thus despite tremendous effort for developing vaccine against
dengue fever in last 70 years there is not approved vaccine yet (36, 37). Due to the
myriad of complications in dengue virus vaccines, drug-based treatments for dengue
fever are promising alternatives. The promise of small-molecule drugs for treating
dengue fever are the inspiration for the work presented in this thesis.
1.4.2. Antibody Dependent Enhancement (ADE)
As mentioned above, vaccination against additional dengue virus serotypes id
complicated due to Antibody Dependent Enhancement (ADE). The phenomenon (ADE)
is when antibodies that are generated against a dengue virus serotype cross react with
another virus serotypes during a second infection, forming non-neutralizing antibody-

,!

!
virus complexes. These complexes bind to the Fc receptors of monocytes-macrophages
causes increasing in higher virus uptake to the cell that results in severe infection (33).
Another important point regarding ADE is that viral antigens are exposed to the
infected cell surface by MHC-antigen complexes, leading the stimulation of CD4+ and
CD8+ T lymphocytes (38, 39). T-cell activation is resulting in high production of
cytokines, interferon-γ (IFN-γ), which activates other B-cells cells, resulting in upregulation of Fc receptor that introduce more interaction sites between non-neutralized
virus-antibody complexes and cell surface (37).

Figure 7. Schematic representation of anti-body dependent enhancement. Figure
reprinted from (37).
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1.4.3. Dengue Virus Protease as a Drug Target
Developing a vaccine that is producing tetravalent antibodies, which are
neutralizing four virus serotypes simultaneously, is extremely difficult. Therefore
different approaches have been taking in dengue fever treatment. Targeting dengue virus
protease, which is a serine protease, is on of the most popular approaches (40). Dengue
virus protease is involved in the post-translational proteolytic processing of the
polyprotein precursor (Fig. 4) and is essential for viral replication and maturation of
infectious dengue virions. Thus there are many studies that are targeting dengue virus
protease for dengue fever treatment (41, 42), but to date no dengue fever treatments of
any kind have made it to market.
1.5 Structure of Dengue Virus Type 2 Protease
Dengue virus protease (NS2B-NS3pro) is a serine protease in peptidase clan PA. The first
structure of dengue virus protease available was 2FOM.pdb (Fig. 8). Dengue virus
protease is also called NS2B-NS3pro because DVP is composed from two pieces of the
DV polyprotein Non-Structural protein 2B (NS2B) and Non-Structural protein 3 (NS3).
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Figure 8. The known crystal structure of wild type dengue virus type II protease. (pdb
ID:2FOM).
The secondary structure shows 56% β-sheet and 12% helical content. The NS3pro
domain (yellow) of dengue virus protease’s structure adopts a chymotrypsin-like fold
with two b-barrels, each formed by six β-strands, with the catalytic triad (His51-Asp75Ser135) located at the cleft between the two β-barrels. In several biochemical studies it
has been shown that the activity of NS3 domain is dependent on the NS2B (magenta) part
of protein (43).
1.5.1 Dengue Virus Protease Chemistry
Given its structure and active site composition, it is believed that dengue virus
protease functions by a similar catalytic mechanism as all related trypsin-like proteases
(Fig. 9).
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Figure 9. The catalytic mechanism of serine proteases. In general it is believed to be
applicable for dengue virus protease. Figure reprinted from [42].
The generic catalytic mechanism of serine protease in general includes the following
steps: i) The protein substrate binds to the surface of the serine protease enzyme in a way
that the bond between P1 and P’1 is situated in the active site of the enzyme. The carbonyl
carbon of this bond makes a close approach to the nucleophilic serine. The serine –OH
attacks the carbonyl carbon on the peptide substrate. The nitrogen of the catalytic
histidine accepts the hydrogen from the -OH group of the active site serine and a pair of
electrons from the double bond of the carbonyl oxygen moves to the oxygen. That results
to formation of a tetrahedral intermediate. Reversal of this tetrahedral intermediate breaks
the bond between the nitrogen and the carbon in the peptide bond (44).
1.5.2 Dengue Virus Type 2 Protease Substrate Specificity
Dengue virus protease has specificity for positively charged amino acids. The preference
for binding peptide substrates has been profiled (Table 1).

%&!

!
Table 1. Dengue virus protease recognizes the basic sequence KRR. These data have
been reprinted from [43].

Boc-GRR-AMC
Bz-nKRR-ACMC
Bz-nKTR-ACMC
Bz-nTRR-ACMC
Bz-TKRR-ACMC
Bz-TTRR-ACMC

0.13 6 0.02
1.4 6 0.1
1.4 6 0.1
0.76 6 0.03
0.20 6 0.01
0.17 6 0.01

150 6 15
12 6 2
34 6 10
46 6 6
11 6 1
76 6 9

840 6 100
112,100 6 18,500
40,300 6 10,200
16,700 6 2,000
18,300 6 2,100
2,200 6 200

The preferred cleavage sites of dengue virus protease contain two basic amino
acids Experiments with peptide substrates have shown that the best cleavage efficiency of
dengue virus protease can be obtained when KRR (Lys-Arg-Arg) tripeptide introduced to
active wild type protease (Table 1). Some work has also focused on assessing the
recognition spectificity for dengue virus protease. For P1’ serine is shown to be the best
of highest protease efficiency (Fig. 10) (45).

Figure 10. Dengue virus protease prefers serine in P1’ and P3’ and a glycine in P4’. This
figure has been reprinted from [43].
1.6 Motivation:
One of the most popular ways for drug development is making a small molecule
based drug that can inhibit the dengue virus protease. The reason for high demand in
finding a molecule that can inhibit dengue virus protease is that dengue virus protease has
a vital role in dengue virus life cycle. Therefore a drug that inhibits dengue protease can
be a good way to treat dengue fever.
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Knowing the active site specificity, drug development has focused on
development of active site inhibitors. There are two main strategies have been taking to
find dengue virus protease inhibitors. One is HTS of small molecule libraries, and the
other is by rational designing peptidomimetics, which aim to active site of protease. One
of the main hurdles in early drug development of these strategies is that the active site of
the dengue virus protease is flat therefore designing inhibitors by structure-based design
is relatively hard.
Another difficulty in efforts to find active site based drug is that dengue virus
protease prefers positively charged amino acids in peptide substrates. Therefore a drug
candidate that targets active site of protease naturally has to be a charged inhibitor.
Because it is hard to synthetize a charged molecule that is orally bioavailable, it is
difficult to design peptidomimetics against dengue protease that can be effective
inhibitors in vivo. Since active site is flat and charged it is also extremely difficult to find
small-molecule inhibitors of the protease.
Finding another site that can be targeted for drug development may open a new
avenue in dengue fever treatment. Allosteric sites are cavities that differ from active site
and available for natural metabolites to bind in these cavities. Binding possible natural
ligands to these allosteric sites regulates protein activity by altering conformational
changes. Allosteric sites can be either cavity are available for natural ligands or
serendipitous cavities which are available to bind a synthetic molecule to it for
therapeutic purpose.
An allosteric site can also lead the discovery of a successful drug against dengue
virus protease, which can be used with an active site-inhibitor drug together. In principle
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combination therapy using an active-site and an allosteric-site inhibitor might be useful.
Disulfide tethering is used for discovering new, serendipitous allosteric sites in dengue
virus protease. A cysteine substitution is made in the enzyme region that we think can
function as an allosteric site upon a compound binding. Then a compound that has a
nucleophilic center for cystein’s attack we introduced in protein, a broadly specific
hydrophobic entity to position in the cavity and a linker between necleophilic center and
hydrophobic part is designed. Enzyme that has engineered cysteine and compound are
incubated together and the enzyme activity is monitored. If mutant enzyme gets inhibited
compound binding is validated by mass spec. And finally if it looks necessary the cocrystal structure of the enzyme with compound is solved to figure out the atomic details
of inhibition mechanism.
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CHAPTER 2
ALLOSTERIC INHIBITION OF THE NS2B-NS3 PROTEASE FROM DENGUE
VIRUS

The contents of this chapter have been published as Muslum Yildiz, Sumana Ghosh,
Jeffrey A. Bell, Woody Sherman and Jeanne A. Hardy 2013 “Allosteric inhibition of the
NS2B-NS3
protease
from
dengue
virus”
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Chemical
Biology
http://dx.doi.org/10.1021/cb400612h.

2.1 Abstract
Dengue virus is the flavivirus that causes dengue fever, dengue hemorrhagic
disease, and dengue shock syndrome, which are currently increasing in incidence
worldwide. Dengue virus protease (NS2B-NS3pro) is essential for dengue virus infection
and is thus a target of therapeutic interest. To date, attention has focused on developing
active-site inhibitors of NS2B-NS3pro. The flat and charged nature of the NS2B-NS3pro
active site may contribute to difficulties in developing inhibitors and suggests that a
strategy of identifying allosteric sites may be useful. We report an approach that allowed
us to scan the NS2B-NS3pro surface by cysteine mutagenesis and use cysteine reactive
probes to identify regions of the protein that are susceptible to allosteric inhibition. This
method identified a new allosteric site utilizing a circumscribed panel of just eight
cysteine variants and only five cysteine reactive probes. The allosterically sensitive site is
centered at Ala125, between the 120s loop and the 150s loop. The crystal structures of
WT and modified NS2B-NS3pro demonstrate that the 120s loop is flexible. Our work
suggests that binding at this site prevents a conformational rearrangement of the NS2B
region of the protein, which is required for activation. Preventing this movement locks
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the protein into the open, inactive conformation, suggesting that this site may be useful in
the future development of therapeutic allosteric inhibitors.
2.2 Introduction
Dengue virus (DENV) is the causative agent in dengue fever, dengue hemorrhagic
disease, and dengue shock syndrome. All four serotypes of dengue virus are transmitted to
humans by the Aedes aegypti and Aedes albopictus mosquitoes (1-6). Globally nearly 2.5
billion people are at risk of dengue virus infection and over 100 million infections are
reported annually (6). Dengue virus infection also causes 22,000 deaths each year in areas
where it is endemic (7). Despite intensive biomedical studies, no vaccine nor drug has
been approved to date (1, 8-10).
Dengue virus contains a positive-strand RNA genome that can be directly
translated into a single polyprotein chain by host-cell translation machinery. The
polyprotein precursor comprises three structural proteins: capsid (C), membrane (M),
envelope (E), and five non-structural proteins NS1-5. In the polyprotein precursor the
proteins are arranged as NH2-C-prM-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5COOH (11-13). Maturation of the precursor is essential for the viral life cycle and
requires post-translational proteolytic processing by the dengue virus protease (NS2BNS3pro) to liberate individual viral proteins from the polyprotein chain. NS2B-NS3pro, a
trypsin-like serine protease, performs the post-translational proteolytic processing of
precursor (14, 15). NS2B-NS3pro cleaves the viral protein at the NS2A/NS2B,
NS2B/NS3, NS3/NS4A and NS4B/NS5 junctions as well as in the capsid protein (16,
17). Full processing releases the viral protease (NS2B-NS3pro), helicase (NS3) (18-20),
methyltransferase (NS5), and RNA-dependent RNA polymerase (NS5) (21). The other
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non-structural proteins such as NS1 and NS2 are involved in the viral replication
complex while NS4 is an integral membrane protein that plays a role in induction of
membrane alteration (22-24).
It is clear that the flavivirus proteases including NS2B-NS3pro are essential for
viral replication and infectivity, as shown by a number of previous studies. For example,
Yellow fever virus genetically modified to contain only inactive NS2B-NS3pro is unable
to infect target cells (25). Similarly, treatment of cells with a peptide that inhibits NS2BNS3pro decreases dengue virus infection by 80% (26). In addition, inhibition of viral
proteases is a well-established route for preventing viral infection in clinical settings. A
large number of HIV protease inhibitors are clinically used to treat HIV infection and
AIDS (for review see(27)). Two hepatitis C virus protease inhibitors recently approved
for therapeutic use have likewise become the standard of care (28). Thus one of the most
prominent attempted strategies for dengue virus therapy has been development of small
compounds that target the active site NS2B-NS3pro (29-33).
NS2B-NS3pro has a catalytic triad (His51 – Asp75 – Ser135) in the active site.
NS2B-NS3pro has a somewhat altered specificity relative to other trypsin-like serine
proteases. The fact that NS2B-NS3pro recognizes only sites that contain two cationic
residues, whereas trypsin recognizes sites containing a single cationic residue, has
necessitated the development of new classes of inhibitors for targeting the active site
(34). The structural boundaries originally annotated within the polyprotein suggested that
the NS3 domain encoded the functional protease. Later studies showed that expression of
NS3 alone did not lead to production of an active protease, however including a portion
of NS2B with NS3 leads full proteolytic activity (16). The crystal structure of NS2B-
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NS3pro from dengue virus type 2 shows that the catalytic triad is located between two βsheets, each formed by six β-strands (Fig. 11).
One of the main hurdles in early drug development against this target has been
that the NS2B-NS3pro active site is flat, so designing inhibitors by structure-based design
has been challenging (35-37). Another difficulty in finding orthosteric drugs is that
NS2B-NS3pro prefers positively charged amino acids in peptide and peptidomimetic
substrates. Charged molecules typically display limited oral bioavailability, furthering the
difficulty in design of peptidomimetics against NS2B-NS3pro that are effective inhibitors
in vivo.
The work described here is based on our hypothesis that an alternative functional
site, such as an allosteric site, might be identified and targeted for drug development. We
define allosteric sites as those regions of the protein that, when bound to a smallmolecule ligand, undergo a change in conformation or an alteration in the conformational
equilibrium that impacts enzymatic function. Allosteric sites have previously been found
to be important in proteases in general (for review see (38, 39), making it likely that
allosteric sites in NS2B-NS3pro likewise could be exploited. In this work we have used
both novel and known cysteine-reactive chemical probes to identify sensitive regions of
NS2B-NS3pro that may serve as functional allosteric sites.
2.3 Results And Discussion
Most studies targeting NS2B-NS3pro by small-molecule inhibitors have focused
on the active site, but unfortunately no drug that inhibits the enzyme via active site
binding has been approved to date. In this work we reason that finding other sites —

&(!

!
potentially allosteric sites that can be targeted for enzyme inhibition — may prove
fruitful in drug development against dengue virus. In this study we have interrogated
potential allosteric sites in NS2B-NS3pro that can be targeted by small-molecule
compounds. Putative allosteric sites spaced across the protein surface were identified by
visual inspection of the crystal structure of unliganded NS2B-NS3pro (PDB: 2FOM, Fig.
11).

Figure 11. NS2B-NS3pro positions interrogated as potential allosteric sites.
(A) Potential allosteric sites were identified based on visual inspection of the known structure of the
wild type protease (NS2B-NS3pro) from dengue virus serotype 2 (PDB: 2FOM). The location of
residues that were substituted by cysteine are drawn as sticks. The active site triad is drawn as balls.
Regions disordered in the crystal structure are drawn as dashed lines. This figure was drawn with
PyMOL.
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Eight individual cysteine residues were introduced near these cavities (Fig. 12A-D) to
provide reactive handles for cysteine-tethering-based covalent-compound binding.

Figure 12A. Surface contours near cysteine substitutions. Putative allosteric sites were predicted by
visual inspection of the published DENV2 NS2B-NS3pro crystal structure (pdb: 2FOM). Cysteines were
introduced in proximity to cavities that were identified on the surface of NS3pro. Residues replaced by
cysteine are shown as spheres in the ribbon diagram, which provides the orientation of the protein. In the
surface respresentation (blue), the replaced residue is shown as green sticks. Among cysteine variants
W83C, T111C and L115C did not show any catalytic activity while the others were as active as wild
type NS2B-NS3pro. Arrows indicate the active site of NS2B-NS3pro.
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Figure 12B. Surface contours near cysteine substitutions. Putative allosteric sites were predicted by
visual inspection of the published DENV2 NS2B-NS3pro crystal structure (pdb: 2FOM). Cysteines were
introduced in proximity to cavities that were identified on the surface of NS3pro. Residues replaced by
cysteine are shown as spheres in the ribbon diagram, which provides the orientation of the protein. In the
surface respresentation (blue), the replaced residue is shown as green sticks. Among cysteine variants
W83C, T111C and L115C did not show any catalytic activity while the others were as active as wild
type NS2B-NS3pro. Arrows indicate the active site of NS2B-NS3pro.
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Figure 12C. Surface contours near cysteine substitutions. Putative allosteric sites were predicted by
visual inspection of the published DENV2 NS2B-NS3pro crystal structure (pdb: 2FOM). Cysteines were
introduced in proximity to cavities that were identified on the surface of NS3pro. Residues replaced by
cysteine are shown as spheres in the ribbon diagram, which provides the orientation of the protein. In the
surface respresentation (blue), the replaced residue is shown as green sticks. Among cysteine variants
W83C, T111C and L115C did not show any catalytic activity while the others were as active as wild
type NS2B-NS3pro. Arrows indicate the active site of NS2B-NS3pro.
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Figure 12D. Surface contours near cysteine substitutions. Putative allosteric sites were predicted by
visual inspection of the published DENV2 NS2B-NS3pro crystal structure (pdb: 2FOM). Cysteines were
introduced in proximity to cavities that were identified on the surface of NS3pro. Residues replaced by
cysteine are shown as spheres in the ribbon diagram, which provides the orientation of the protein. In the
surface respresentation (blue), the replaced residue is shown as green sticks. Among cysteine variants
W83C, T111C and L115C did not show any catalytic activity while the others were as active as wild
type NS2B-NS3pro. Arrows indicate the active site of NS2B-NS3pro.
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W83C, T111C and L115C did not show any catalytic activity while the others were as
active as wild type NS2B-NS3pro. Arrows indicate the active site of NS2B-NS3pro.
Wild-type (WT) NS2B-NS3pro does not have any intrinsic cysteine residues and
therefore provides an ideal scaffold for this interrogation. The effects of single cysteine
additions on enzyme activity were determined using a GRR-aminomethylcoumarin
fluorogenic substrate (Table 2).
Table 2. Kinetic properties of NS2B-NS3pro variants.
Variant

KM
(µM)

kcat
(min-1)

wild type
333 ± 21 1.5 ± 0.001
E19C
321 ± 39
1.0 ± 0.10
L31C
343 ± 26
1.0 ± 0.23
W83C
N.D.
N.D.
E86C
290 ± 51
0.8 ± 0.20
N105C
271 ± 23
1.6 ± 0.03
T111C
N.D.
N.D.
L115C
N.D.
N.D.
A125C
235 ± 45
1.1 ± 0.30
N.D. - not detectable; N.T. – not tested

kcat/KM
(min-1/µM)
4.5 x10-3
3.1 x10-3
2.9 x10-3
2.7 x10-3
5.9 x10-3
4.6 x10-3

Molar Ratio
of DTNB
binding
0
1
1
0.2
1
1
1
1
1

Molar Ratio
of BAClMK
binding
0
1
0.8
N.T.
1
1
N.T.
N.T.
1

The majority of the cysteine substitutions had no effect on catalytic activity; however,
substitution of cysteine for Trp83, Thr111, or Leu115 fully abolished enzymatic function.
Trp83 is a fully buried residue, so it is likely that formation of a cavity and destabilization
of the folded form of NS2B-NS3pro results in loss of activity. Thr111 and Leu115 are
mostly solvent exposed, so their loss of function is more surprising. Nevertheless, since
most of the variants retained catalytic properties similar to the wild-type NS2B-NS3pro,
we were able to undertake a cysteine scanning and tethering approach to identify
potential allosteric sites.
Our approach to identify new allosteric sites on NS2B-NS3pro shows some
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similarities to previous versions of cysteine tethering that have lead to identification of
allosteric sites (40-44), but is unique in that it requires only a small panel of cysteinereactive probes (Fig. 12A).
Original tethering libraries intended for ligand discovery were composed of a
large number (1,200-40,000) of specific monophores (unique chemical entities or
pharmacophores) each attached to a weakly electrophilic thiol moiety. Our panel for
allosteric site discovery, is composed of monophores that we hypothesized would be
broadly reactive, and are attached to highly reactive electrophiles. We included the
biarylether monophore because in screening of large tethering libraries this monophore
was broadly reactive, probably due to its hydrophobic nature and shape, which can be
accommodated in many cavities and crevices on protein surfaces. In addition, we
included more reactive electrophilic warheads including chloromethylketones and
activated disulfides.
Each active cysteine variant was incubated with the panel of cysteine-reactive
probes. To monitor the accessibility of the introduced thiols we used DTNB, a
quantitative cysteine-reactive colorimetric reagent, which also functions as an inhibitor of
A125C NS2B-NS3pro (Fig. 12). Most of the cysteine insertions resulted in shortening of
the side chain at the insertion position, with the exception of A125C, which extends the
side chain by addition of a thiol. Nevertheless, we found that all of the introduced
cysteines were able to bind to DTNB and BAClMK (Table 2), suggesting that all are
accessible and reactive. After incubation with the panel of probes, the remaining NS2BNS3pro activity was measured. All of the introduced cysteines in active versions of
NS2B-NS3pro are available, reactive, and are fully modified by the probes (Table 2).
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Figure 13. Only A125C is sensitive to chemical probes amongst the sites tested.
(A) Cysteine-reactive probes used in this study. (B) A125C is fully inhibited by all of the cysteine
reactive probes including Aldrithiol, DTNB and biarylchloromethylketone (BAClMK), but not by
similar non-reactive probes such as biarylamine. Compound binding at all other sites had no affect on
function. (C) The inhibition of A125C by DTNB is relieved by subsequent treatment with the reductant
β-mecaptoethanol (β-ME), demonstrating that covalent attachment to the cysteine at A125C is critical
for inhibition.
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Two of the inactive variants (T111C and L115C) are fully susceptible to reactions with
the introduced cysteine, but W83C only partially reacted. Although the introduced
cysteines in the active versions of NS2B-NS3pro are capable of becoming fully modified,
we found that only the A125C variant was inhibited by compound binding (Fig. 12B).
A125C was fully inhibited by DTNB, Aldrithiol, or biarylchloromethylketone (BAClMK,
Fig. 14A), which form covalent adducts to Cys125, indicating that these chemical probes
are effective inhibitors at this site. Inhibition by DTNB could be fully reversed by the
addition of the reductant (β-mercaptoethanol), indicating that binding was cysteine
dependant (Fig. 12C). A125C was only weakly inhibited by the non-cysteine-reactive
biarylamine (Fig. 12B), suggesting that covalent binding is required for inhibition. A
thiol-based biaryl compound (biarylthiol, Fig. 14B) failed to inhibit A125C under these
conditions, suggesting that a more reactive electrophile is required for reaction and
inhibition. This also suggests that any interaction between the biaryl monophore and the
protein is transient or weak. Covalent modification of A125C by DTNB or BAClMK was
readily observed by mass spectrometry (Table 3), but no binding to WT NS2B-NS3pro
was observed.
This further demonstrates that both DTNB and BAClMK react with the
introduced cysteine at A125C but do not react with the active site nucleophile, Ser135, or
any other functional group present on the protein. This suggests that NS2B-NS3pro
inhibition is not due to a random mechanism and that inhibition is mediated by compound
binding specifically to the introduced cysteine at residue position 125.
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Figure 14. Synthetic scheme for production of biarylchloromethylketone and biarylthiol.
(A) The biarychlormethylketone (BAClMK) is a novel cysteine-reactive compound that is composed of
a broadly-specific biarylether monophore attached to a highly reactive electrophilic chlormethylketone
warhead via a linker. (B) A cysteine-reactive compound that contains the same broadly-specific
hydrophobic monophore (biarylether), a linker and a thiol group for disulfide exchange.
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Table 3. Molecular weights observed for NS2B-NS3 variants alone or following
reaction with cysteine reactive compounds

Protein

Calculated (Da)

Observed (Da)

WT

26,296

26,295

WT + BAClMK

26,650

26,294

WT + DTNB

26,494

26,294

A125C

26,329

26,332

A125C + BAClMK

26,682

26,684

A125C + DTNB

26,527

26,526

BAClMK – Biarylchlormethylketone, DTNB -5,5'-dithiobis-(2-nitrobenzoic acid)

To further probe the mechanism of inhibition at A125C, we measured the circular
dichroism (CD) spectra to monitor large-scale changes in the structure upon cysteine
introduction and compound tethering. Introduction of A125C had no pronounced effect
on the CD spectra, suggesting that any changes in the structure of protein were minor
(Fig. 15). This finding is also consistent with the observation that the catalytic properties
of A125C were essentially unchanged from WT. Binding of DTNB also had no
noticeable effect on the CD spectra, suggesting that the mechanism of DTNB-based
inhibition was not through unfolding or disruption of the global NS2B-NS3pro structure.

')!

!

Figure 15. A125C NS2B-NS3pro achieves the same global structure as wild-type before or after
DTNB binding.

The nearly superimposable circular dichroism (CD) spectra for NS2B-NS3pro wild-type
and A125C in the presence or absence of the inhibitor DTNB suggests that neither
cysteine substitution nor compound binding have any large-scale or disruptive effects on
the structure of the protein.
Given that DTNB binding did not impact the overall structure, we explored
whether compound binding would impact the stability of the protein. Thermal
denaturation of NS2B-NS3pro as monitored by circular dichroism showed that WT,
A125C, and DTNB-bound A125C all had Tms of 50±1°C, suggesting that DTNB binding
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has no effect on stability. In addition, we monitored the impact of DTNB binding on
other cysteine insertion variants. E19C, L31C, E86C, and N105C versions of NS2BNS3pro all also showed similar Tms to WT and A125C and changes in Tm of 1°C or less
upon binding of DTNB (Fig. 16), suggesting that the mode of interaction is similar
between all of the variants.

Figure 16. DTNB induces minimal changes in thermal stability.
The thermal stability as assessed by intrinsic tryptophan fluorescence of NS2B-NS3pro E19C, L31C,
E86C and N105C in the presence or absence of the inhibitor DTNB are similar to eachother and to WT
and A125C (Fig. 14), suggesting that neither cysteine substitution nor compound binding have any
significant effect on stability or on the folded/unfolded equilibrium for the protein.
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Thermal denaturation of NS2B-NS3pro results in an unusual, but not
unprecedented (45), gain in CD signal; therefore, we also monitored stability using
intrinsic tryptophan fluorescence. A125C showed stability indistinguishable from WT
and DTNB binding also had no impact on stability (Fig. 17). The above findings suggest
that the structures of A125C and the A125C complexes with ligands are similar to WT
NS2B-NS3pro and that covalent compound binding resulting in the inhibited form is not
altering the folding-unfolding equilibrium.
One of the most common sources of false positives in early drug discovery is
formation of organic small-molecule colloidal aggregates or small molecule-protein coaggregates, which can sometimes inhibit enzymes nonspecifically (46). The reasons for
these phenomena are not well understood but a possible mechanism is that single enzyme
molecules bind tightly and non-specifically to small compound aggregates, thereby
leading to enzyme inactivation in protein:small-molecule co-aggregates. This kind of
inhibition can be problematic, particularly with hydrophobic compounds such as the
probes used here, and in our case could lead to spurious identification of allosteric sites.
To investigate whether this type of mechanism is involved in inhibition of A125C, we
subjected A125C to size exclusion chromatography, native gel electrophoresis, and
dynamic light scattering (Fig. 18).
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Figure 17. Inhibitor binding does not affect A125C thermal stability.
The thermal stability as assessed by intrinsic tryptophan fluorescence of NS2B-NS3pro wild-type and
A125C in the presence or absence of the inhibitor DTNB are similar, suggesting that neither cysteine
substitution nor compound binding have any significant effect on stability or on the folded/unfolded
equilibrium for the protein.
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WT, A125C, and DTNB-bound A125C all showed identical retention on a sizeexclusion column, which was consistent with a monomer of 26 kDa (Fig. 18A).
Likewise, WT, A125C, and DTNB-bound A125C all migrated at the same position on a
native gel, suggesting that all three species are monomers of similar mobility (Fig. 18B).
This also indicates that no intermolecular disulfides are forming that could be responsible
for the observed loss of activity for DTNB-bound A125C. Finally, A125C had a
comparable distribution of particle sizes by dynamic light scattering, further suggesting
that the inhibited form of A125C is fully monomeric, soluble, and well behaved, even
though it is fully inhibited (Fig. 18C). These analyses all suggest that no spurious or
aggregation-mediated mechanisms of inhibition are responsible for the loss of activity
conferred by DTNB and the other A125C inhibitors.
Together, these results suggest that targeting the 120s loop region, or potentially a
cavity or crevice near the Ala125 site, with a small molecule inhibitor may be an
effective way to achieve enzyme inhibition. To visualize the mechanisms of DTNB and
BAClMK inhibition of NS2B-NS3pro, we sought to determine the crystal structures of
A125C in complex with DTNB or BAClMK. We first determined the structures of
unliganded WT and A125C (Table 4) under pH 5.5 conditions, similar to those observed
previously for WT NS2B-NS3pro from dengue virus serotype 2 (DENV2, (35)). Both
WT and A125C had the same overall fold as the published structure of WT NS2BNS3pro (PDB: 2FOM (35)) except that the 120s loop (residues 117-122, which are ~15Å
away from the substrate-binding groove) was in a different conformation.
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Figure 18. A125C is monomeric even in the presence of covalent inhibitors.
(A) The oligomeric states of wild-type and A125C NS2B-NS3pro in the presence or absence of
the inhibitor DTNB were investigated by size exclusion chromatography. The similar retention
times and elution profiles suggest that neither the introduced cysteine nor DTNB have any
impact on oligomeric state, which is consistent with a monomer of 26 kDa. (B) Wild-type and
A125C NS2B-NS3pro in the presence or absence of the inhibitor DTNB all display similar
migration patterns in native gel electrophoresis indicating that neither cysteine substitution nor
DTNB change the oligomeric state. (C) A125C NS2B-NS3pro in the presence or absence of the
inhibitor DTNB show similar profiles by dynamic light scattering suggesting that DTNB does
not influence the aggregation state of the protein.
Because two of the covalent inhibitors, BAClMK and DTNB, do not react to form
a covalent adduct with A125C at pH 5.5 but do bind and robustly inhibit NS2B-NS3pro
at pH 8.5, we sought alternative, neutral pH crystallization conditions. Extensive
screening of unliganded NS2B-NS3pro failed to produce any new crystallization
conditions. Numerous screens of NS2B-NS3pro covalently modified with BAClMK or
DTNB also failed to produce crystals under any conditions, so we developed a method
for transferring the unliganded A125C pH 5.5 crystals to pH 8.5 without negatively
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impacting diffraction (Table 4). Crystals subsequently soaked with BAClMK
failed to diffract (Table 4).
Table 4. Crystallographic data collection and refinement statistics for NS2B-NS3pro variants
WT
WT
A125C
A125C
pH 5.5
pH 8.5
pH 5.5
pH 8.5

A125C
pH 8.5
+ DTNB

Wavelength (Å)
Diffraction Resolution (Å)a

1.0
50-1.46
(1.49-1.46)

1.0
115-1.53
(1.56-1.53)

1.0
50-2.37
(2.41-2.37)

1.0
58-2.65
(2.7-2.65)

1.0
44-1.70
(1.73-1.70)

Measured Reflections (n)
Unique Reflections
Completeness (%)
Redundancya
I/σ(I) a
Rsym
Space group
a (Å)
b (Å)
c (Å)
α = γ = β (°)
Refinement statistics
No. waters
Rwork/Rfree (%)
RMSD bond length (Å)
RMSD bond angle (°)
Average B-factor (Å2)
Ramachandran plot
Core (%)

180652
36703
99.4 (99.9)
4.9 (4.3)
36.0 (2.1)
0.065 (0.51)
C2221
59.5
62.0
114.1
90

221559
32669
99.3 (84.9)
3.6 (2.3)
4.6 (2.6)
0.086 (0.51)
C2221
59.9
62.5
114.6
90

31758
9008
96.6 (98.8)
3.5 (3.2)
8.4 (2.0)
0.145 (0.54)
C2221
60.7
62.1
115.0
90

43218
6357
99.2(98.4)
6.8 (6.6)
9.3 (1.5)
0.17 (0.96)
C2221
60.2
61.0
114.0
90

60921
18461
85.3 (79.2)
3.3 (4.6)
30.9 (1.9)
0.11 (0.66)
C2221
61.4
62.1
114.4
90

103
20.3/22.3
0.028
2.7
24.2

169
19.6/23.3
0.011
1.5
26.51

14
21.5/27
0.015
1.83
53.4

36
22.7/24.0
0.013
1.71
48.5

30
21.4/24.1
0.013
1.99
27.4

191
(99.0%)
2 (1.0%)
0 (0.0%)
4M9K

193
(99.5%)
1 (0.5%)
0 (0%)
4M9M

189
(97.9%)
4 (2.1%)
0 (0.0%)
4M9I

189
(97.4%)
4 (2.1%)
1 (0.5%)
4M9F

195 (98.5%)

Allowed (%)
Disallowed (%)
a

3 (1.5%)
0 (0.0%)
4M9T

Data in parentheses are for the highest resolution bin.

Fortunately, we were able to soak DTNB into NS2B-NS3pro crystals, yielding viable
crystals that diffracted to 1.74 Å resolution (Table 4). Analysis of this structure in detail
suggested that conformational changes in the 120s loop could be important.
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In the absence of substrate, DENV2 NS2B-NS3pro can adopt what is termed the
open (inactive) conformation, wherein the NS2B region (Fig. 19A) sits at the base of the
protein below the active site (Fig. 19B). No crystal structures of NS2B-NS3pro from
DENV2 have been reported with substrate or active-site inhibitors bound, however the
molecular details of the closed (active) conformation are available based on homology to
the structure of NS2B-NS3pro from dengue virus serotype 3 (DENV3), which is 68%
identical to that of DENV2 (Fig. 19C). A structure of the closed form of DENV3 NS2BNS3pro was determined in the presence of a substrate-like active-site inhibitor (Nle-GlyLys-Lys-aldehyde). In the presence of active-site inhibitor, the NS2B region undergoes a
large conformational rearrangement such that residues 73-88 sit above the active site near
the 120s loop (Fig. 19D). It appears that this conformational rearrangement is required
for activity and is essential for substrate binding and catalytic turn over. Recent extensive
NMR analysis suggests that in solution NS2B-NS3pro favors the closed conformation in
the presence and absence of substrate (47). Thus, flexibility of the NS2B region of the
protease is critical for function.
The 120s loop also appears to be quite flexible; we and others have observed a
number of conformations of this loop in unliganded versions of WT and A125C NS2BNS3pro (Fig. 19E). The conformation of the 120s loop in the DTNB-soaked structure is
incompatible with the active (closed) conformation of the NS2B region. Superposition of
the DTNB-soaked structure with the active conformation of NS2B-NS3pro from DENV3
shows a steric clash between the 120s loop and the active conformation of NS2B (Fig.
19F).
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Figure 19 A-D. The 120s loop is flexible and undergoes conformational changes in
the presence of DTNB.(A) Domain architecture and numbering of NS2B-NS3pro from
dengue virus serotype 2 (DENV2). (B) The structure of unliganded (open, inactive)
NS2B-NS3pro from DENV2 (yellow and purple ribbons, PDB: 2FOM). Ala125 is drawn
as spheres; the catalytic triad is drawn as sticks. (C) Domain architecture and numbering
of NS2B-NS3pro from dengue virus serotype 3 (DENV3), which is 68% identical to
DENV2 NS2B-NS3pro. (D) The structure of DENV3 NS2B-NS3pro (green and purple
ribbons, PDB: 3U1I) bound to the substrate-like, active-site inhibitor benzoly-Nle-LysArg-Arg-aldehyde (white sticks) shows the active conformation of NS2B-NS3pro. Upon
substrate binding the NS2B region (purple) from residues 63 to 88 moves around the
hinge at residue 63 to interact with the Ala125-adjacent region between the 120s and
150s loops. A125C is drawn as spheres; the catalytic triad is drawn as sticks.

A second model of inhibition by DTNB and BAClMK also involves NS2B
reorganization. Modeling covalent binding of either DTNB (Fig. 19G) or BAClMK (Fig.
19H) to C125, we see that a likely conformation for the inhibitor is protruding toward the
120s loop in a position that would sterically clash with the active conformation of the
NS2B region. This steric clash would prevent the NS2B region from adopting the closed
(active) conformation thereby shifting the ensemble toward the open (inactive)
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conformation we observe in the DTNB-soaked structure

Figure 19 E-H. (E) The 120s loop shows conformational flexibility. The structures of
NS2B-NS3pro WT at pH 5.5 (olive) or 8.5 (dark olive) and A125C at pH 5.5 (dark blue)
or 8.5 (light blue) all show the same conformation of the 120s loop. In contrast, in the
presence of DTNB the 120s loop moves to a new (down) conformation (orange). The
previously reported WT structure at pH 5.5 (PDB: 2FOM, yellow) shows an intermediate
conformation of the 120s loop indicating that this loop is flexible and able to adopt a
range of conformations. (F) The conformation of the 120s loop in the presence of DTNB
(orange) sterically clashes with the substrate-bound conformation that has been observed
in DENV3 NS2B-NS3pro (purple and green). Residues 73 to 88 from the NS2B region
(purple) move from the open position in the absence of substrate to the closed position,
which is incompatible with the conformation observed in the presence of DTNB. (G)
Computational model of DTNB bound to A125C showing steric clash between DTNB
and the NS2B region of the active form of DENV3 NS2B-NS3pro (green and purple
strands). (H) Computational model of BAClMK bound to A125C showing steric clash
between BAClMK and the NS2B region (purple strands). These structures were drawn
with PyMOL
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We favor this model for explaining the inhibition of NS2B-NS3pro activity with three
structurally divergent compounds, all of which could utilize the same mechanism. Due to
the covalent nature of the interactions between the probes and NS2B-NS3pro variants, we
expect that if any other interrogated sites were equally susceptible to allosteric inhibition,
our approach would have also recognized those sites. Given that only A125C was
inhibited by any of the compounds, we posit that this region is one of the most
susceptible regions of the protein for allosteric inhibition. We predict that small
molecules that bind between the 120s loop and the 150s loop (residues 153–164, which
sit below the S3 subsite) will serve as effective inhibitors of NS2B-NS3 protease activity
(Fig. 20).

Figure 20. The A125 site is conserved in the NS2B-NS3 proteases from dengue virus and
West Nile virus. The A125-adjacent site that is susceptible to inhibition by DTNB, BAClMK
and Aldrithiol lies between the 120s and 150s loops in DENV NS2B-NS3pro (purple and green
strands) and in West Nile virus NS2B-NS3pro (gray).
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While we were not able to observe any density for DTNB attached to the cysteine
residue at position 125 (Cys125), we are certain that the reaction between Cys125 and
DTNB occurred in the crystals due to the appearance of a yellow color resulting from the
DTNB reaction. In contrast, the same reaction did not occur with mother liquor alone.
The presence of large (30Å diameter) solvent channels in the NS2B-NS3pro crystals
(Fig. 21) appear to provide ample access of DTNB to the A125C residues throughout the
crystals.

Figure 21. Solvent channels in the A125C crystals allow access of DTNB to C125.
The crystallographic packing of NS2B-NS3pro A125C features large solvent channels,
approximately 30Å in diameter, observable as cavities between protein monomers. The
introduced cysteine (yellow spots) are readily accessible inside these solvent channels.
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To thoroughly explore the possibility of weak density or multiple conformations
for DTNB we used placement based on Glide (48, 49) with density-guided and forcefield-based refinement. While the overall model statistics improve with the PrimeX
refinement (Table 4), no models could be generated that place DTNB in areas of
significant electron density. As such, we hypothesize that DTNB may have incompletely
reacted, dissociated after freezing or during synchrotron radiation or is dramatically
disordered.

Figure 22. Region surrounding residue Cys 125 in the structure of A125C +
DTNB, pH 8.5. All residues in this view are from the B chain. Hydrogen atoms have
been omitted for clarity. Green contours are from a 2Fo-Fc map contoured at 1.0 σ,
showing the electron density calculated from the observed diffraction data. The red and
blue contours are from an Fo-Fc map contoured at 3.0 sigma, indicating a possible excess
and deficiency of electrons in the atomic model, respectively. The Fo-Fc contours shown
in this view are close to the noise level. The absence of any large Fo-Fc peaks indicates
that the model fits the observed data well. No indication of DTNB binding can be seen in
the crystallographic results, even though a chemical reaction with DTNB was clearly
observed both in the crystal and in solution, and even though the addition of DTNB to the
crystals changed the cell constants and the observed protein structure as described above.
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Although we were unable to observe any electron density for DTNB attached to
the cysteine at position 125 (Fig. 22), the presence of DTNB in the crystal does have a
notable effect on the structure of A125C we observe. In addition to the altered
conformation of the 120s loop, residues Thr77–Met84 are ordered in the DTNB-soaked
structure — these residues were disordered in all structures to date of DENV2 NS2BNS3pro including the high-resolution structures 2FOM (1.5 Å) and the WT pH 5.5
structure reported here (1.46 Å). We assume that the NS2B region of NS2B-NS3pro is in
equilibrium between the closed (active) and open (inactive) conformations; it appears that
the presence of DTNB may stabilize the open (inactive) conformation. Only in the
presence of DTNB can we observe density for the Thr77-Met88 stretch, which is ordered
by crystal contacts between Thr76 and Asn119 in the 120s loop (Fig. 23). Thus, one
model of DTNB-based inhibition is that this steric clash between the flexible 120s loop
and the active conformation of the NS2B region is responsible for the inhibitory activity
of DTNB.
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Figure 23. Crystal contacts between the 120s loop and NS2B in the presence of DTNB. One crystal
contact between N119 in the 120s loop and T77 in NS2B appear to be responsible for maintaining the
observed conformation of the 120s loop.
2.4 Conclusions
The approach we developed in this work allowed us to identify the Ala125
allosteric site in NS2B-NS3pro and is promising for future applications due to its
simplicity and feasibility. In this study, interrogating just eight single-site cysteine
substitutions with a panel of just five chemical probes, three of which are commercially
available, we were able to identify a productive allosteric site that was susceptible to full
inhibition by three diverse molecules. The approach we describe is also generally
applicable for allosteric site identification in a wide range of protein targets. This
cysteine-based approach is particularly well suited to target proteins like NS2B-NS3pro
that lack native cysteines. The lack of cysteines need not be a requirement for success,
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provided that at least some of the probes have no effect on the function of the native
target protein or as is often the case, removal of reactive surface cysteines has no impact
on function.
Prior to this study several pieces of evidence have suggested that the dengue virus
protease family should be susceptible to allosteric inhibition. The 3F10 antibody disrupts
the interaction of NS2B with NS3 in vitro, suggesting that allosteric inhibition of NS2BNS3pro should be possible (50). Antibody-based inhibition of proteases has been used for
half a century, and some of inhibitory antibodies utilize allosteric mechanisms (for
review see (51). For example, another trypsin-like protease, hepatocyte growth-factor
activator, can be allosterically inhibited by the Fab75 antibody through binding an activesite adjacent loop (residues 99–102) (52). Although the homologous region is a short turn
in NS2B-NS3pro (residues 72–74) and thus not useful as an allosteric epitope, we can
envision that a similar inhibitory mechanism could be used by an NS2B-NS3pro 120s- or
150s-specific antibody. Finally, compounds derived from in silico docking experiments
that function as non-competitive inhibitors have also been reported (53). While we are
unable to ascertain whether an innate biological role of the Ala125 allosteric site exists, it
is our aim to continue to assess the native role and exploit this site chemically with
specific, non-covalent ligands or antibodies.
The prevalence of diseases caused by flaviviruses is rapidly expanding, raising
interest in the proteases across this family as drug targets. A similar conformational
change in the NS2B region is observed for the protease from West Nile virus, which
shares 46.8% identity with DENV2 NS2B-NS3pro, suggesting that the mechanism of
activation may be conserved across the family. In the unliganded state, the NS2B region
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of NS2B-NS3pro from West Nile virus is in the open conformation. When substrate
binds, the NS2B region moves above the 120s loop (Fig. 20) adopting the closed
conformation. Given the similarity in the mechanism of activation, we predict that the
protease from West Nile virus would also be allosterically inhibited in a similar manner
at the region of the 120s and 150s loops. In fact, uncompetitive/allosteric inhibitors of
West Nile virus have been previously described, but no structural information on the site
of binding has been reported. It is tempting to consider whether the Ala125 region could
be the target of the pyrazole-ester-based West Nile NS2B-NS3 protease inhibitors (54,
55).
Allosteric inhibition of dengue virus protease is of potential interest due to the
lack of clinically available inhibitors that target the NS2B-NS3pro active site. All small
molecule binding sites, whether they be allosteric or otherwise, are composed of three
components: a cavity (which may be induced by a small molecule), polar residues that
contribute directional forces allowing specificity, and hydrophobic interactions that
provide the enthalpy for binding. The region identified near Ala125 appears to possess
these three essential elements. Ala125 sits between the 120s and 150s loops, which our
work has shown to be very flexible. Thus it appears that the shape of this cavity is
malleable, potentially accommodating a number of chemical entities in addition to the
BAClMK and DTNB. This region also has a number of appropriately positioned polar
residues (e.g. Asn119, Thr118, and Thr156) for providing specificity and hydrophobic
residues (e.g. Phe116, Ile123, Val154, Val155, and Val162) for providing binding
affinity (enthalpy). Our studies use a covalently linked version of NS2B-NS3pro that has
been widely utilized and characterized (35). Recently Keller and coworkers have shown
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that unlinked NS2B-NS3pro exhibits slightly higher activity (up to 5 fold) and appears to
prefer the closed conformation even prior to substrate binding (56). Nevertheless, we
anticipate that the allosteric site identified at Ala125 will also be effective against the
unlinked NS2B-NS3pro, but that remains to be tested. Development of non-covalent
inhibitors that utilize the site we have identified is not trivial but prior work has
demonstrated that covalent tethering hits can effectively be developed into non-covalent
inhibitors (40, 57, 58). Thus we envision that both structure-guided rational approaches
that take loop flexibility into account and empirical screening for inhibitors against
NS2B-NS3pro may be fruitful routes to further exploitation of this allosteric site.
Drug resistance becomes an issue in any rapidly evolving system, including
pathogenic human viruses such as dengue virus, so the development of allosteric
inhibitors requires careful consideration. While combination treatments affecting two
protein targets have been widely used in viral therapy, the combination of active-site and
allosteric inhibitors against a single protein target has not been tested. We hypothesize
that simultaneously targeting both the active and allosteric sites of NS2B-NS3pro should
delay the onset of resistance over single-site inhibition. At the very least, the system
described here will enable us to measure development of resistance in single-target
combination therapy and directly assess whether active- or allosteric-site inhibitors are
more prone to development of resistance in NS2B-NS3pro. In the best-case scenario, one
might envision development of clinically useful allosteric inhibitors that target the
allosteric site we have identified.
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2.5 Methods
2.5.1 Dengue Virus Serotype 2 Protease (DENV2 NS2B-NS3pro) Expression
Constructs. The wild-type dengue virus serotype 2 protease (NS2B-NS3pro) construct
encoding a synthetic gene (Celtek Bioscience) for E. coli codon-optimized N-terminally
His6-tagged dengue virus serotype 2 protease (DENV2 NS2B-NS3pro, Fig. 24) gene was
constructed by ligation into the XhoI/BamHI sites of the pET15b vector (Stratagene).
This construct expresses a protein comprising amino acids His6-NS2B (4395)GGGGSGGGG-NS3pro (1185). Amino acid substitutions as described were introduced
by the Quikchange® site-directed mutagenesis in this construct. All DNA sequences
were validated by DNA sequencing (Genewiz).

Figure 24. Domain and construct architecture for dengue virus protease NS2B-NS3pro.
(A) The dengue virus protease construct used in these studies encodes the NS2B cofactor region (purple)
covalently linked to NS3pro (yellow) via a Gly4-Ser-Gly4 linker.. For purification purposes a His6-tag
(gray) was linked to NS2B via a thrombin cleavable site (TCS; black).

2.5.2 Cysteine Variant Purification. NS2B-NS3pro expression constructs were
transformed into the BL21 (DE3) T7 Express strain of E. coli (New England Biolabs).
Cultures were grown in 2xYT media with ampicillin (100 mg/L, Sigma-Aldrich) at 37°C
until they reached an optical density at 600 nm of 0.8. The temperature was reduced to
18°C and cells were induced with 1 mM IPTG (Anatrace) to express protein. Cells were
harvested after 18 hrs expression and pelleted by 5 Krpm centrifugation in a SLC4000
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rotor (Sorvall). Cell pellets were stored at –80°C, freeze-thawed and lysed by
microfluidizer (Microfluidics, Inc.) in a buffer containing 50 mM Tris pH 8.5, 50 mM
NaCl, 5% glycerol and 2 mM imidazole (Lysis buffer). Lysed cells were centrifuged at
17 krpm to remove cellular debris. The supernatant filtered in an 0.22-µm filter was
loaded onto a 5-mL HiTrap Ni-affinity column (GE, Healthcare) equilibrated with lysis
buffer. The column was washed with a buffer of 50 mM Tris pH 8.5, 50 mM NaCl, 5%
glycerol and 10 mM imidazole, and the protein was eluted with the buffer containing 50
mM Tris pH 8.5, 50 mM NaCl, 5% glycerol and 100 mM imidazole.
The eluted fractions were diluted 6-fold with 50 mM Tris pH 8.5 buffer, to
decrease the salt concentration. This protein sample was purified further by anion
exchange chromatography. The partially purified sample was loaded onto a 5-mL HP
High Q column (GE Healthcare) and eluted with a linear NaCl gradient. NS2B-NS3pro
eluted in a buffer of 50 mM Tris pH 8.5, 150 mM NaCl. The eluted protein was incubated
with thrombin during dialysis against 50mM pH 8.5 Tris at 4°C overnight to cleave the
His6 tag. The following day the protein sample was loaded onto 5-mL HiTrap Ni-affinity
column (GE Healthcare) to remove the cleaved His6 tag and the thrombin. The His6-free
protein sample was concentrated to 5 mL and loaded to Hiload Superdex 75 26/60 sizeexclusion column equilibrated with lysis buffer. Samples were eluted with lysis buffer
and fractions were stored at –80°C in the lysis buffer conditions. The identity of the
purified DENV2 NS2B-NS3pro and variants were analyzed by SDS-PAGE to be 99%
pure and ESI-MS was used to confirm the mass of all proteins used.
2.5.3 Kinetics Of Cysteine-Substituted Variants. For kinetic measurements of NS2BNS3pro activity, 300 nM-purified NS2B-NS3pro was monitored over the course of 20
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min in a NS2B-NS3pro activity assay buffer containing 100 mM Tris pH 9.0. For
substrate titrations, a range of 0-1mM fluorogenic substrate, GRR-AMC, (N-acetyl-GlyArg-Arg-AMC (7-amino-4-methylcoumarin); Ex 365 nm / Em 495 nm; International
peptides) was added to start the reaction. Assays were performed in duplicate at 37°C in
100 µL volumes in 96-well microplate format using a Spectramax M5 spectrophotometric
plate reader (Molecular Devices). Initial velocities versus substrate concentration were fit
to rectangular hyperbola using GraphPad Prism (Graphpad Software) to determine kinetic
parameters KM and kcat. Enzyme concentrations were determined by monitoring
absorbance at 280 nm using a nano-drop (Thermo Scientific) instrument. The effect of
probes on cysteine variants was determined by incubation of 1 µM of each NS2B-NS3pro
variant with 100 µM of BAClMK, biarylamine or 10 µM of aldrithiol or DTNB for 1
hour prior to performing the activity assay as described above.

2.5.4 Mass Spectrometry. NS2B-NS3pro A125C in Tris pH 8.5, 50mM NaCl and 5%
glycerol was diluted in 0.1% formic acid to a final concentration of 5 µM in a 200 µl
volume and analyzed on Qstar-LC electrospray ion trap mass spectrometer (Applied
Biosystems) with an ESI source and positive ion polarity. A PROTO 300 C4 5 µM
column (Higgins Analytical, Inc.) was used to desalt the protein on the LC prior to
ionization in the mass spectrometer. The MS instrument system was equipped with an
HP1100 HPLC system (Hewlett-Packard). Scanning was carried out between 600-1400
m/z. A mass range between 20 kDa and 30 kDa was deconvoluted to obtain
corresponding sample mass. The expected mass for the unliganded form of A125C was
26329 Da; we observed 26332 Da as expected.
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To validate the compound binding, 10 µM of NS2B-NS3pro A125C was
incubated with 100 µM DTNB (5,5'-dithiobis-(2-nitrobenzoic acid)) or 100 µM
BAClMK in Tris pH 8.5, 50 mM NaCl and 5% glycerol buffer for 1 hr to ensure full
binding. After a 1 hr incubation, the sample buffer was exchanged for 0.1 % formic acid
and analyzed as above. The expected mass for DTNB bound form of A125C was 26,527
Da; we observed the major species (>95%) as 26,526 Da, which clearly indicates
covalent compound binding. Likewise, the expected mass for BAClMK-bound of A125C
was 26,682 Da; we observed the major species (>95%) as 26,684 Da, which clearly
indicates covalent compound binding.
2.5.5 Determination Of Molar Binding Ratio Of DTNB and BAClMK
The total protein concentrations of NS2B-NS3pro WT, E19C, L31C, E86C and N105C
were determined by measuring 280 nm absorbance and a molar extinction coefficient of
41970 M-1 cm-1. Samples in 0.1 M pH 8.5 Tris, 1 mM EDTA were then incubated in 50
µM DTNB for 30 minutes. The concentration of sulfhydryl for each sample was
determined by measuring the absorbance (412 nm) of the released yellow product of the
DNTB reaction with free thiol, 2-nitro-5-thiobenzoate. The released 2-nitro-5thiobenzoate concentration was calculated using Beer’s Law and the molar extinction
coefficient for 2-nitro-5-thiobenzoate of 14,150 M-1cm-1. The concentration of total
protein was compared to the concentration of released 2-nitro-5-thiobenzoate, to calculate
the DTNB molar binding ratio.
To determine the molar binding ratio of BAClMK, NS2B-NS3pro variants in 0.1
M pH 8.5 Tris were incubated in 500 µM BAClMK for 1 hour. Afterward unreacted
BAClMK was removed and samples were exchanged to a buffer that contained 1mM
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EDTA and 0.1 M pH 8.5 Tris using a NAP25 column (GE Healthcare). Each sample was
then incubated in 50 µM of DTNB for 30 minutes to assess the presence of free thiol.
Released 2-nitro-5-thiobenzoate was monitored at 412 nm and concentration was
calculated as described above. The molar binding ratio of BAClMK was calculated to as
the total protein minus the free thiols measured after BAClMK incubation.
2.5.6 Circular Dichroism (CD). Circular dichroism experiments were carried out on a
J720 circular dichrometer equipped with peltier temperature controller (JASCO) at 20°C.
The secondary structure contents of 5 µM WT NS2B-NS3pro, apo A125C and liganded
A125C in 10 mM pH 8.5-phosphate buffer were observed by monitoring circular
dichroism signal between 250 and 190 nm. A125C was labeled in lysis buffer (50mM pH
8.5 tris, 5% glycerol and 50 mM NaCl) with 50 µM DTNB (5,5'-dithiobis-(2-nitrobenzoic
acid)) (Thermo Scientific) and buffer exchanged to 10 mM pH 8.5 phosphate buffer prior
to the measurement.
2.5.7 Size Exclusion Chromatography. The oligomeric state of the NS2B-NS3pro WT
or A125C unliganded or in various compound-bound states was determined by analysis
on a Superdex 200 10/300 GL (GE Healthcare) gel-filtration column. NS2B-NS3pro
samples were concentrated in 50 mM NaCl, 5% glycerol and pH 8.5 Tris in a 3K
molecular weight cutoff membrane concentrator (Sartorium Stedim Biotech) to 2 mg/mL.
Samples were filtered and loaded onto the column. Protein was eluted with 50 mM NaCl,
5% glycerol and pH 8.5 Tris buffer. Peak fractions were identified by monitoring
absorbance at 280 nm and the eluted proteins were analyzed by SDS-PAGE. Molecular
weight standards from the gel-filtration calibration kit LMW (GE Healthcare) were run
prior to experiment with the same conditions. A standard curve was drawn to determine
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the oligomeric state of NS2B-NS3pro. According to standard curve the expected
retention volume for a monomer of NS2B-NS3pro (26 kDa) was 15.40 mL.
2.5.8 Dynamic Light Scattering (DLS). 2 mg/mL of unliganded or DTNB-labeled
A125C in 0.1 M Bis-tris propane pH 6.0 and 0.02 % w/v n-Octyl-b-D-glucoside at 20°C
was analyzed on a Zetasizer Nano ZS (Malvern) with a temperature control and a 633 nm
He-Ne laser for backscattering at 173°. 15 measurements of 10s duration were averaged
per analysis. The distributions of the mean apparent translational diffusion coefficients
(DT) were calculated by fitting the DLS autocorrelation functions using non-negative
constrained least squares (NNLS). The distribution of apparent sizes dh was obtained
from the distribution of mean apparent translational diffusion coefficient (DT) where k is
the Boltzmann constant and η is the solvent viscosity, which was assumed to be that of
water.
Rapp = kT / ( 6 πηDT)

2.5.9 Intrinsic Tryptophan Fluorescence. A125C was incubated with 10 µM DTNB in
Tris pH 8.5, 50 mM NaCl and 5% glycerol buffer for 1 hr. The sample was buffer was
exchanged to lysis buffer (50mM pH 8.5 Tris, 50mM NaCl and 5% glycerol) using a
NAP5 column (GE Healthcare). The intrinsic tryptophan fluorescence of 500 nM WT or
A125C, unliganded or in complex with DTNB, in lysis buffer was measured (Ex.
290/Em. 300-400 nm) on a Quantum Master 30 spectrofluorometer (PTI) as a function of
temperature ranging from 25 to 85 °C. Temperature was controlled via circulating water
bath. Resultant data were fit to a Gaussian hyperbole and the wavelength at the maximum
absorption (λmax) found by calculating the point at which the 1st derivative was equal to 0
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(Mathematica, Wolfram Research, Inc). λmax shifted from 338 nm (100% folded) to 350
nm (0% folded) as temperature increased from 25 to 85°C . The fraction of folded NS2BNS3pro was calculated at each temperature by monitoring the λmax value.
2.5.10 Crystallization and Data Collection. Purified NS2B-NS3pro, wild-type or
A125C, in 50 mM Tris pH 8.5, 5% glycerol, and 50 mM NaCl was concentrated using
Amicon Ultrafree 3K NMWL membrane concentrators (Millipore) to 15 mg/mL. The
crystals grew in 0.1 M Sodium Acetate pH 5.5, 40% PEG 200 in 1 week at 4°C
temperature in a hanging drops. For the pH 8.5 WT or A125C structures, crystals were
manually transferred to new mother liquor containing Tris pH 8.5 and 40% PEG 200 and
soaked for 12 hrs. For A125C pH 8.5 + DTNB or + BAClMK structures, A125C crystals
equilibrated at pH 8.5 were soaked for 6 hrs in the new mother liquor containing 5 mM
DTNB (5,5'-dithiobis-(2-nitrobenzoic acid)) (Thermo Scientific) or BAClMK. All
crystals were flash frozen in liquid nitrogen (LN2) and stored in LN2. Complete data sets
for all unliganded proteins were collected at X6A beamline at 1 Å Brookhaven National
Laboratories National Synchrotron Light Source (Upton, NY). Data for A125C pH 8.5 +
DTNB were collected using synchrotron radiation of 1.0Å at APS 24-ID-C. Indexing
and integration were carried out with MAR XDS(59). Data were scaled using
SCALA.(60)
2.5.11 Structure Determination. All data were processed and scaled in HKL2000 in the
orthorhombic space group C2221 with CCP4(61). The search model successfully used for
molecular replacement using Phaser(62) was unliganded DENV2 NS2B-NS3pro (PDB
ID 2FOM, 1.5 Å resolution). The initial model building in Coot(63) and NCS restrained
refinement using CCP4i. The structures were refined using automated refinement in
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Refmac(64) and TLS to a final R/Rfree as listed for the various structures in Table 4. For
A125CpH 8.5 + DTNB we performed additional refinement using the program
PrimeX,(65) which provides both the advantages of all-atom model refinement(66) as
well as a specialized facility for investigating ligand binding. The water model from the
original REFMAC-refined structure, as well as approximately 10% of the residues with
the highest real-space R-factors, were removed from the working model. Reciprocalspace minimization of coordinates and temperature factors, and hydrogen-bond
optimization, were applied periodically as atoms were added to the model. Missing
internal residues were built using the PrimeX automated loop refinement tool. Similarly,
N-terminal and C-terminal ends of the model chains were extended as far as the electron
density permitted. At this stage additional analysis was performed of the residual electron
density, during which no feature consistent with DTNB binding was detected. Waters
were added by PrimeX at the 4σ level on Fo-Fc maps, and were screened manually to
include only those with spherical electron density and a hydrogen-bonding interaction
with the protein. The additional refinement decreased the free R-factor by 2.9%.
2.5.12 Synthetic Materials and Methods. All solvents and reagents used were of
highest

purity

available.

4-phenoxyaniline,

3-mercaptopropanoic

acid,

3,3’-

Dithiodipropionic acid were purchased from Acros Organics. 1H-NMR spectra were
recorded on Bruker 400 spectrometer

and chemical shifts (δ) are reported in ppm

downfield from the internal standard (TMS).
2.5.13 Synthesis of Biarylchloromethylketone (BAClMK, 1, Fig 14A)
Synthesis of N-(4-Phenoxyphenyl)succinamic acid ethyl ester (3,

Fig. S2A). 4-

phenoxyaniline (2 (Fig. 14A), 0.5g, 2.7 mmol) was dissolved in 3 mL dichloromethane
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(DCM). The solution was cooled and triethylamine (750 µl, 5.4 mmol) was added
followed by dropwise addition of ethylsuccinylchloride (400 µl, 2.8 mmol) while
maintaining the temperature of the reaction mixture at 0°C. The resultant solution was
stirred at 0°C for 1-2 hr and at room temperature for 6-7 h. After complete consumption
of the starting material, the reaction mixture was diluted with DCM and the product was
successively washed with 0.5 N HCl, water and finally with brine solution. The organic
phase was dried over sodium sulfate (Na2SO4) and evaporated under vacuum to obtain 3
(Fig. 14A) as a brown solid (0.507 g, 60%) with 90-95% purity. 1H-NMR (CDCl3, 400
MHz) δ (ppm) 1.25 (t, J = 7.2 Hz, 3H), 2.64 (t, J = 6 Hz, 2H), 2.74 (t, J = 6.5 Hz, 2H),
4.15 (q, J1 = 7.1 Hz, 2H), 6.96 (d, J = 8.7 Hz, 4H), 7.06 (t, J = 7.4 Hz, 1H), 7.3 (t, J = 8.2
Hz, 2 H), 7.45 (d, J = 8.8 Hz, 2H), 7.68 (1H, NH).
Synthesis of N-(4-Phenoxyphenyl)succinamic acid (4, Fig. 14A). Compound 3 (Fig. 14A)
(0.5 g, 1.6 mmol) was dissolved in 10 mL THF; and 20% sodium hydroxide solution
(NaOH) (5 mL) was added into the reaction mixture. The resulting solution was refluxed
for 3 hr and cooled to room temperature. The solvent was removed under vacuum and the
resulting aqueous solution was acidified with 2 N HCl. The precipitate formed upon
acidification was filtered, washed with minimum water and dried to obtain 0.4 g of (90%)
brown solid. 1H-NMR (DMSO (d6), 400 MHz) δ (ppm) 2.57 (t, J = 6.5 Hz, 2H), 2.68 (t, J
= 6.4 Hz, 2H), 6.9 (t, J = 8.7 Hz, 4H), 7.01 (t, J = 7.4 Hz, 1H), 7.25 (t, J = 8.4 Hz, 2 H),
7.45 (d, J = 8.9 Hz, 2H), 7.68 (1H, NH). 1H-NMR (CH3OH (d4), 400 MHz) δ (ppm) 2.6
(s, 4H), 6.9 (t, J = 8.9 Hz, 4H), 7.01 (t, J = 7.4 Hz, 1H), 7.25 (t, J = 8.4 Hz, 2 H), 7.45 (d,
J = 8.9 Hz, 2H), 7.68 (1H, NH).
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Synthesis of Nα-((S)-4-chloro-3-oxobutan-2-yl)-Nδ-(4-phenoxyphenyl)succinamide (1,
Fig. 14A). Compound 4 (Fig. 14A) (0.12 g, 0.42 mmol) was dissolved in THF (5 mL)
and allowed to react with isopropylchloroformate (66 µl, 0.5 mmol) in the presence of Nmethylmorpholine (60 µl, 0.55 mmol) for 1.5 hr at -20°C to activate the acid
functionality. The amine salt of the L-alanine chloromethylketone (5, 0.094 g, 0.46
mmol) in DMF solution was added into the resulting solution by maintaining the
temperature at -20 oC. The reaction mixture was stirred for another 1 hr at -20°C and
allowed to stir at room temperature for overnight. The solvent was evaporated and
extracted with ethylacetate. The ethylacetate fraction was washed successively with
saturated sodium bicarbonate (NaHCO3), 0.5 N HCl and finally with brine solution. The
crude product obtained as brown solid was then purified by flash column chromatography
using 4% MeOH/CH2Cl2 as the eluent to obtain 1 as a light brown solid (0.05 g, 31 with
98-99% purity. 1H-NMR (CDCl3 + CD3OD, 400 MHz) δ (ppm) 1.28 (d, J = 6.5 Hz, 3H),
2.52 (d, J = 6.0 Hz, 2H), 2.56 (d, J = 5.7 Hz, 2H), 4.23 (dd, J1 = 12.7 Hz, J2 = 16.04 Hz,
2H), 4.5 (q, J1 = J2 = 7.2 Hz, 1H), 6.86 (d, J = 8.0 Hz, 4H), 6.98 (t, J = 7.4 Hz, 1H), 7.2
(t, J1 = J2 = 7.9 Hz, 2H), 7.4 (d, J = 8.9 Hz, 2H), 7.7 (1H, NH).,
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C-NMR (CDCl3 +

CD3OD), 120 MHz) δ (ppm) 14.56, 29.4, 30.52, 45.62, 51.8, 117.35, 118.4, 120.8, 122.1,
128.74, 133.2, 152.5, 156.8, 170.45, 172.55, 201.31., MS (FAB) 389.1(M+H), 388.8
(calculated mass).
2.5.14 Synthesis of Biarylthiol (1, Fig 14B)
Synthesis of 3-(tritylthio)propanoic acid, 3 (Fig. 14B). In an air-dried flask (3.0 mL,
0.034 mole) 3-mercaptopropanoic acid was dissolved in 60 mL DCM. Trityl chloride
(9.53 g, 0.034 mole) dissolved in THF, was slowly added into the reaction mixture at RT.
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After 15 min a white solid started forming and the resultant reaction mixture was allowed
to stir for 14 hr at room temperature. Finally, the reaction mixture was filtered and
washed three times with DCM. The filtrate was concentrated, which led to the formation
of a solid. The solid was washed with minimal amount of dichloromethane. The
combined solid was almost 95% pure and obtained as 90% isolated yield. The obtained
product was directly used for the next step without further purification. 1H-NMR (CDCl3,
400 MHz) δ (ppm) 2.24 (t, J = 7.3 Hz, 2H), 2.46 (t, J = 7.3 Hz, 2H), 7.21-7.23 (m, 2H),
7.26-7.3 (m, 8H), 7.41-7.43 (m, 5H).
Synthesis

of

N-(4-phenoxyphenyl)-3-(tritylthio)propanamide,

4

(Fig.

14B).3-

(tritylthio)propanoic acid (0.15 g, 0.92 mmol) was dissolved in 5 mL THF. The reaction
mixture was cooled to -15°C to -20°C and a mixture of N-methylmorpholine (0.26 mL,
2.4 mmol) and isopropyl chloroformate (0.14 mL, 1.1 mmol) were added dropwise while
maintaining the temperature at -20°C. The resultant solution was further stirred at -20°C
for 90 min to complete acid activation step. 4-phenoxybenzamine (0.17 g, 0.92 mmol)
was dissolved in anhydrous THF and was added into the reaction mixture at -20°C. The
resultant mixture was stirred at -20°C for 1 hr and slowly allowed to reach at room
temperature. The solvent was evaporated and extracted with ethylacetate. The
ethylacetate fraction was washed successively with saturated NaHCO3, and finally with
brine solution. The crude product was repeatedly washed with a minimal amount of
ethylacetate and the filtrate was removed. By repeating this process three to four times a
95-98% pure brown solid product was obtained as (0.33 g) 70% isolated yield. 1H-NMR
(CDCl3, 400 MHz) δ (ppm) 2.14 (t, J = 7.2 Hz, 2H), 2.6 (t, J = 7.2 Hz, 2H), 6.94-6.97 (m,
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4H), 7.07 (t, J = 7.4 Hz, 1H), 7.21-7.31 (m, 12H), 7.4 (d, J = 7.4 Hz, 2H), 7.45 (d, J = 7.6
Hz, 5H).
Synthesis of 3-Mercapto-N-(4-phenoxyphenyl)propanamide, 1 (Fig. 14B). In an air-dried
flask, 3.1 mL trifluoroacetic acid was added to a stirring solution of 4 (0.096g, 0.186
mmol) in 6.2 mL DCM at room temperature. The yellow color produced was then
quenched by the addition of 60 µl of Triethylsilane (TES). The reaction mixture was
stirred at room temperature for 2 hr and then concentrated. After removal of the volatiles
under vacuum, the solid residue was washed successively with hexane to remove
triphenylmethane. Then the solid was dissolved in minimal volume of ethylacetate and
the product was precipitated by using an excess of diethylether. This process was
repeated two to three times to afford a white-colored solid at a 70% (0.07 g) isolated
yield. 1H-NMR (CD3COCD3, 400 MHz) δ (ppm) 1.5 (s, 1H), 2.7 (t, J = 7.2 Hz, 2H), 2.97
(t, J = 7.0 Hz, 2H), 6.93-6.97 (m, 4H), 7.08 (t, J1 = 7.9 Hz, J1 = 7.0 Hz, 1H), 7.32-7.36
(m, 2H), 7.67-7.69 (d, J = 7.9 Hz, 2H), 9.4(s, 1H).
2.6 Accession Codes
The structures described here have been deposited in the Protein Data Bank with
Assession codes 4M9F, 4M9I, 4M9K, 4M9M and 4M9T.
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CHAPTER 3
CONFORMATIONAL REARRANGEMENT OF NS2B REGION IS CRITICAL FOR
CATALYTIC ACTIVITY OF DENGUE VIRUS NS2B-NS3 PROTEASE

The contents of this chapter have been submitted to Protein Science as: Muslum Yildiz,
Yunlong Zhao and Jeanne A. Hardy “Conformational rearrangement of NS2B region is
critical for catalytic activity of dengue virus NS2B-NS3 protease.”
3.1 Abstract
The protease (NS2B-NS3pro) from dengue virus plays an important role in the dengue
viral lifecycle and has therefore become a potential drug target for dengue fever
treatment. NS2B-NS3pro appears to be a very flexible enzyme. Data from
crystallography and NMR have indicated NS2B-NS3pro transitions between two widely
divergent structural states. NS2B-NS3pro can transition from an open conformation, with
the NS2B region away from the active site, to a closed conformation, with the NS2B
region near the active site. It appears that the open conformation is inactive while the
closed conformation appears to be active and able to bind substrate. To date, the relative
roles and equilibrium between these states is not known and the resting conformational
state of NS2B-NS3pro is also under discussion. We hypothesize that attaining both the
open and closed conformations are critical for NS2B-NS3pro function. To interrogate the
importance of the various conformational states, we developed versions of NS2B-NS3pro
that allow us to trap the enzyme in several distinct conformations. Our data from these
variants suggest that NS2B-NS3pro rests in the open conformation prior to substrate
binding. In addition, catalytic turnover of NS2B-NS3pro appears to be dependent not
only on the movement of NS2B, but also on the flexibility of the core of the protease.
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3.2 Introduction
Dengue fever, dengue hemorrhagic disease, and dengue shock syndrome are
mosquito born diseases caused by infection by dengue virus (1-6). Dengue virus is a
flavivirus in the flaviviridae family, which consists of over 70 viruses including West Nile
and Yellow Fever viruses.(7, 8) The four antigenically distinct dengue virus serotypes
(DENV1-DENV4) share over 65% genetic homology (9, 10). Infection with any of these
individual serotypes can result in full medical manifestation of dengue fever, dengue
hemorrhagic disease or dengue shock syndrome. These diseases remain a global health
threat for the nearly 2.5 billion people in infected tropical regions with over 100 million
infections(6) and 22,000 dengue virus-related deaths reported annually (11). Presently
there are neither approved treatments nor vaccines for dengue fever, dengue hemorrhagic
disease or dengue shock syndrome (1, 12-14).
The linear, positive polarity RNA genome of dengue virus is translated by the
host cell protein translation system into a single-chain polyprotein precursor that consists
of three structural proteins that form the viral coat: capsid (C), membrane (M), envelope
(E) and five non-structural proteins: NS1-5 arranged as C-prM-E-NS1-NS2A-NS2BNS3-NS4A-NS4B-NS5.(15-17) Maturation of the precursor is one of the key steps in the
viral life cycle and requires post-translational proteolytic processing by the dengue virus
protease (NS2B-NS3pro) to release individual viral proteins from the intact polyprotein
chain (18, 19). NS2B-NS3pro cleaves the viral protein at the NS2A/NS2B, NS2B/NS3,
NS3/NS4A and NS4B/NS5 junctions as well as within the capsid protein (20, 21). Full
processing releases the viral protease (NS2B-NS3pro), helicase (NS3),(22-24)
methyltransferase (NS5), and RNA-dependent RNA polymerase (NS5) (25).
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Due to its critical role in polyprotein maturation and viral infectivity, NS2BNS3pro has been studied intensively. While the protease was originally believed to be
encoded by NS3, early structural and biochemical studies showed that the protease is a
two-component system such that a portion of NS2B in addition to the protease portion of
NS3 is also required for proteolytic activity (19). Two types of protein constructs have
been used for NS2B-NS3pro expression. In one type, a Gly4SerGly4 linker links NS2B to
NS3pro while the second type requires co-expression of the unlinked NS2B and NS3
regions.(26) The catalytic activity is similar between the linked and unlinked protein
constructs, with the unlinked showing approximately 0 to 5-fold greater activity
depending on the protein construct used (26). Structural studies on NS2B-NS3pro from
DENV1 (27), DENV2 (28), DENV3 (29) and West Nile virus (WNV) (28) indicate that
NS2B-NS3pro shares similar structural features across the closely related flavivirus
genus. On the other hand there is some controversy about the flexible nature of NS2BNS3pro, particularly of that expressed from linked and unlinked protein constructs.
Recent paramagnetic relaxation enhancement studies by NMR on unlinked ligand-free or
liganded NS2B-NS3pro show that NS2B is dominantly in closed conformations in the
presence or absence of substrate, but a full structure by NMR has not yet been attained
(26). On the other hand, high-resolution crystal structures of the linked NS2B-NS3pro
without substrate from DENV2 (28), DENV3 (29) and WNV (30) show NS2B in the
open conformation. NS2B-NS3pro adopts a closed conformation upon substrate binding
as was seen in the DENV3 (29) and WNV (28) structures, however a structure of
substrate bound DENV2 NS3B-NS3pro has not yet been attained, despite efforts by
many groups (28, 29). Thus, there is lack of data regarding the conformation of the NS2B
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region for DENV2 NS2B-NS3pro crystallographically or from a full NMR structural
determination. Although NMR and X-ray studies suggest different equilibrium between
closed and open states of NS2B in unlinked and linked forms of NS2B-NS3pro, data
from both techniques are in agreement about the flexible nature of NS2B in both the
unlinked and linked form and all data imply an equilibrium between the open and closed
conformations. Despite growing evidence for significant flexibility in NS2B region, the
importance of this flexibility for the proteolytic activity of NS2B-NS3pro has not been
investigated.
Here we report that flexibility in the core region of NS3 is essential for catalytic
activity of NS2B-NS3pro. Our data also suggest that the closed conformation of NS2B is
required for dengue virus protease activity and preventing NS2B mobility within the core
of the protease also negatively impacts catalysis by NS2B-NS3pro.
3.3 Results and Discussion
While NS2B-NS3pro from DENV2 has only been observed crystallographically in the
open (inactive) conformation (Fig. 25A), its similarity to NS2B-NS3pro from DENV3
and WNV as well as NMR evidence suggest that also exists in the closed
(active/substrate-bound) conformation (Fig. 25B). To probe the importance of these
conformational changes on the activity of DENV2 NS2B-NS3pro (Fig. 25 A & B), we
devised an experimental plan to trap NS2B-NS3pro in various conformations.

We

identified potential pairs of residues that when replaced with cysteine should result in the
formation of an intramolecular disulfide in one particular conformation. The modeled
pairs of cysteine residues were evaluated using MODIP(31) to score the probability of
disulfide formation between candidate pairs. Ultimately we identified and constructed six
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disulfide pairs (Table 5).

Figure 25 Cystein traps are shown in the figure.(A) The protease from DENV2 is
composed of residues 43 to 95 from NS2B (magenta) and residues 1 to 185 from NS3
(yellow) which we have connected with a Gly4SGly4 linker (black line). All crystal
structures to date have shown the NS2B-NS3pro in the open conformation (ribbon
diagram). (B) The homologous protease from DENV3 is composed of residues 43 to 93
from NS2B (magenta) and residues 1 to 185 from NS3 (green). This protease has been
observed in the closed upon active-site substrate binding when the NS2B region
(magenta) undergoes a large conformational change. (C) Pairs of residues (spheres) that
have been replaced by cysteine to trap NS2B-NS3 into the indicated conformations under
oxidizing conditions. The closed conformation structure is only available for DENV3 in
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which residues 73 is asparagine (N73) whereas DENV2 residue 73 is isoleucine (I73).

The I73C/P106C pair is in close proximity in the open conformation, but far apart
in the closed conformation (Fig. 25C); thus formation of intramolecular disulfides should
trap this variant in the open conformation. The A125C/V162C pair is in nearly the same
position in both the open and closed states (Fig. 25C), so intramolecular disulfides are
compatible with either the open and closed states. The V97C/N105C pair is far apart in
both the open and closed states (Fig 25C), so intramolecular disulfides should trap an
intermediate state that is neither open nor closed. None of these double cysteine
substitutions had any negative effect on expression levels or the catalytic properties of
NS2B-NS3pro (Table 5) suggesting that these cysteine substitutions are benign at all of
Table 5. Kinetic parameters for WT and double cysteine insertion variants of DENV2
NS2B-NS3pro.

WT
I73C / P106C
A125C / V162C
V97C / N105C
I25C / W83C
N105C / F116C
V126C / G159C

KM
(µM)
333 ± 21
1110 ± 79
732 ± 49
633 ± 30
N.D.
N.D.
N.D.

kcat
(min-1)
1.5 ± 0.001
0.3 ± 0.11
0.9 ± 0.11
1.3 ± 0.10
N.D.
N.D.
N.D.

kcat/KM
(x10 min-1/µM)
4.5
0.27
1.2
2
-3

N.D.; Not Detectable
these locations. Although we constructed a number of other double cysteine substitution
variants (e.g. I25C/W83C, N105C/F116C and V126C/G159C, Table 5), we were unable
to identify any double cysteine substitution pairs that would be expected to trap the
closed state of NS2B-NS3pro without negatively impacting the intrinsic function of the
protein.
In addition, for several other sites identified to trap NS2B-NS3 in the closed
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conformation, even the single alanine substitution variants, L75A, I77A, T78A and I79A
were inactive, precluding use of those sites for building disulfide-mediated traps. The
sensitivity of this region is likely due to the fact that the residues that move into close
proximity in the closed conformation also are critical for binding substrate and are
therefore cannot be substituted by cysteine without negatively impacting function. Thus
we did not pursue additional cysteine traps for the closed conformation.
To monitor the effect of formation of intramolecular disulfide bonds on activity,
each NS2B-NS3pro variant was incubated with a range of cystamine concentrations.
Cystamine has the appropriate reduction potential to catalyze formation of disulfide
bonds. As expected, the wild-type enzyme, which lacks any intrinsic cysteine residues
was unaffected by cystamine (Fig. 26). All of the cysteine traps, I73C/P106C,
A125C/V162C and V97C/N105C became completely inactive in the presence of
increasing concentrations of cystamine. This effect was most pronounced for
V97C/N105C, which was fully inactivated at 100 mM cystamine. All of the mutants
became fully inhibited at 500 mM cystamine (Fig. 26) so this concentration of oxidant
was used in all subsequent experiments.
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Figure 26. The effect of cystamine on variants is shown in the figure.The
catalytic activity of wild-type NS2B-NS3pro was unaffected by the addition of the
oxidant cystamine. All of the double cysteine substitution variants were inhibited by
cystamine, which catalyzed formation of disulfide bonds. % activity represents the
activity of the oxidized form relative to the reduced form of each variant, which was set
to 100%.

It is clear that the loss in activity is disulfide dependent, since the catalytic activity
of all of the double cysteine substitution variants could be completely recovered by
reducing all disulfide bonds using the strong reductant, β-mercaptoethanol (Fig. 27). The
recovery of activity suggests that all of the inactivating disulfides are reversible and
reductant accessible.
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Figure 27. Inhibition of the disulfide-locked NS2B-NS3pro variants. In the +cystamine
oxidizing conditions (gray bars) was fully reversed by the addition of the reductant βmercaptoethanol (β-ME) (white bars). WT NS2B-NS3pro, which lacks any cysteine
residues, was not influenced by the presence of either oxidant or reductant.

Interpretation of our results hinges on the exclusive formation of intramolecular
disulfides. Thus it is critical to assess the level of the desired intramolecular disulfides
relative to other undesirable states such as intermolecular disulfides (crosslinks), free
cysteine thiols or cystamine-modified cysteine residues. The free thiol concentration of
the NS2B-NS3pro variants following oxidation was measured using DTNB, a
quantitative, thiol-reactive reagent (Table 6). No free thiols were detected in the oxidized
forms of V97C/N105C, A125C/V162C or I73C/P106C indicating that all of the thiols
were present in an oxidized form, presumably as a mixed disulfide in an intra- or
intermolecular disulfide with another cysteine or exogenous cystamine (Table 6).
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The oxidized forms of the double cysteine variants were subjected to mass spectrometry

Table 6. Molecular weights and DTNB binding capacity of NS2B-NS3pro variants.
Mass calculateda
Mass observed
Molar ratio of DTNB
(Da)
binding in oxidized form
(Da)
A125C/V162C
28,082
28,082
0.0
I73C/P106C
28,043
28,043
0.0
V97C/N105C
26,290
26,290
0.0
a
The masses have been calculated to reflect the formation of a single disulfide bond.

analysis. In all of the variants the expected molecular mass was observed and no mixed
disulfides resulting from a cystamine adduct were detected (Table 6). Together these two
observations suggest that all of the cysteines in oxidized V97C/N105C, A125C/V162C
and I73C/P106C form disulfides with other protein cysteines but not mixed disulfides
with cystamine.
To appropriately interpret the effect of disulfide formation on activity, it is
essential to assess whether intramolecular disulfides are exclusively formed. We
recognize that the presence of intermolecular disulfide-mediated aggregates could
confound our interpretation. The inhibited forms of the disulfide-trapped proteins were
subjected to native agarose gel electrophoresis and size exclusion chromatography to
assess the effect of disulfide bond formation on aggregation. WT, V97C/N105C and
I73C/P106C all migrate as unaggregated monomers on non-reducing native agarose gels
(Fig. 28A). A125C/V162C appears to be partially aggregated (~40% as quantified by
densitomertry) in its reduced state and only slightly more aggregated (~50%) after
oxidation by cystamine (Fig. 28A) indicating that the full inhibition of A125C/V162C
observed upon cystamine treatment can not be due to the small change in the aggregated
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fraction. A similar trend was observed by size exclusion chromatography: V97C/N105C
and I73C/P106C both migrate as unaggregated monomers with similar retention profiles
in the absence or presence of cystamine, whereas A125C/V162C migration is just slightly
altered in the presence of cystamine (Fig. 28B & C), also suggesting that a small amount
of aggregation is occuring. Thus all three variants, I73C/P106C, A125C/V162C and
V97C/N105C, form predominantly intramolecular disulfide bonds and all three variants
are fully inhibited when intramolecular disulfides are formed. Further, it is clear that
inactivation of all the double cysteine variants is dependant on formation of disulfide
bonds since activity can be fully recovered by reduction of disulfides (Fig. 27).
Therefore, we conclude that formation of intramolecular disulfide locks in each of the
variants results in inactivation of NS2B-NS3pro.
We hypothesized that locking NS2B-NS3pro into particular conformations could
impact the overall stability of the protein and provide insights into the functional effects
of the conformational locks. We have shown previously that a number of single cysteine
substitution variants do not impact the thermal stability of NS2B-NS3pro even when
covalently modified by thiol-reactive compounds.(32)
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Figure 28. Native gel.(A) Native agarose gel analysis of WT and NS2B-NS3pro variants
in oxidizing and reducing conditions. WT, I73C/P106C and V97C/N105C variants are
monomeric indicating intramolecular disulfide formation. 40-50% of A125C/V162C is
aggregated under both reducing and oxidizing conditions. (B) Size exclusion
chromatography monitored at 280 nm. (C) Retention times for NS2B-NS3pro variants
under native and oxidizing (+ cystamine) conditions.

,)!

Similarly, in the reduced form all of the double cysteine substitution variant had a similar
thermal stability to WT as assessed by circular dichroism (Fig. 29), although the intrinsic
thermal stability of I73C/P106C was slightly increased relative to WT.

Figure 29. The thermal stability of each NS2B-NS3pro variant. Thermal stability of each
variant in oxidizing and reducing conditions were determined by following circular
dichroism signal at 222 nm in a temperature range of 25 - 90 °C.
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On the other hand, oxidized I73C/P106C, A125C/V162C and V97C/N105C were
significantly stabilized, by 10, 6 and 5°C respectively. This implies that locking the
NS2B-NS3pro into the open or an intermediate conformation presents a thermodynamic
barrier to unfolding, as might be expected. These data may also indicate that the open
conformation is more stable than the closed conformation at least in the absence of
substrate.
All data presented thus far are consistent with the hypothesis that each of these
three disulfides can lock the protein into an inactive, monomeric conformation. DENV2
NS2B-NS3pro contains five ordered tryptophan residues (Fig. 30), which serve as useful
internal monitors for overall protein conformation.

Figure 30. The five tryptophans in DENV2 NS2B-NS3pro (gray/blue spheres).
They are useful monitors for the folded state of the proteins. W61 is in the NS2B portion
of the protein (purple ribbons), which undergoes a large conformational change upon
moving from the open (yellow ribbons) to closed (green/purple ribbons) conformation.
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In particular W61 is in the NS2B region of the protein and should undergo a large
conformational rearrangement in transitioning from the open to closed conformation.
A125C/V162C fluorescence intensity dropped by 40% in the oxidized form (Fig. 31),
which could be the result of the aggregation that we observed following oxidation (Fig.
28)

Figure 31. Intrinsic tryptophan fluorescence of each NS2B-NS3pro variant. It was
monitored in oxidizing and reducing conditions and compared to wild type.
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V97C/N105C showed a notable change in both intensity and emission maximum, which
is consistent with formation of an intermediate conformation that is neither the open nor
closed form of NS2B-NS3pro. Intriguingly, I73C/P106C showed the same intrinsic
tryptophan fluorescence spectrum as WT in both the oxidized and reduced states. This
suggests that no global conformational changes occur upon locking the protein into the
open conformation. This observation is of note since recent NMR studies have suggested
that NS2B-NS3pro exists in the closed conformation in solution even prior to substrate
binding.(26) These tryptophan fluorescence data suggest that NS2B-NS3pro exists in the
open conformation even prior to substrate binding or oxidation of the I73C/P106C
disulfide.
All three of our disulfide locks are capable of inactivating NS2B-NS3pro. The
fact that I73C/P106C inactivates NS2B-NS3pro is consistent with prior data and the
prevailing paradigm, indicating that the open conformation is an inactive conformation
and NS2B-NS3pro must adopt the closed conformation to bind and turn over substrate.
Inactivation by locking NS2B-NS3pro into a V97C/N105C disulfide-mediated
intermediate can also be rationalized in terms of the prevailing paradigm. One can readily
envision that this intermediate prevents formation of either the closed or open forms of
the enzyme. The finding that formation of the A125C/V162C disulfide is capable of
inactivating NS2B-NS3pro is more surprising. The modeled geometry of this disulfide is
very similar to that observed in both the open and closed forms of NS2B-NS3pro (Fig.
32), requiring a movement of less than one angstrom to achieve the disulfide-bonded
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conformation. This suggests that in addition to the closed conformation, rigidification of
the protein in the core in the A125/V162 region by the presence of a disulfide is likewise
inactivating. Clearly, NS2B-NS3pro is a very flexible enzyme, given the large
conformational changes that can and do occur in the NS2B region.

Figure 32. The relative positions of A125 and V162 in the open DENV2 structure
and closed (DENV3) structure are similar to that modeled when an A125C-V162C
disulfide are formed.

Our findings indicate that flexibility of the entire core of the protein may be required
to enable the transition between the closed and open conformations which leads to the
activity of NS2B-NS3pro. This observation is relevant in selecting the types of inhibitors
that may be useful for targeting NS2B-NS3pro in dengue fever therapies.
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3.4 Methods

3.4.1 Dengue Virus Serotype 2 Protease (DENV2 NS2B-NS3pro) Expression
Constructs. The wild-type dengue virus serotype 2 protease (NS2B-NS3pro) construct
encoding a synthetic gene (Celtek Bioscience) for E. coli codon-optimized N-terminally
His6-tagged dengue virus serotype 2 protease (DENV2 NS2B-NS3pro) gene was
constructed by ligation into the XhoI/BamHI sites of the pET15b vector (Strategene).
This construct expresses a protein comprising amino acids His6-NS2B (43-95)GGGGSGGGG-NS3pro (1-180). Amino acid substitutions as described were introduced
by the Quikchange® site-directed mutagenesis in this construct. All DNA sequences
were validated by DNA sequencing (Genewiz).
3.4.2 Cysteine Variant Purification. NS2B-NS3pro expression constructs were
transformed into the BL21 (DE3) T7 Express strain of E. coli (New England Biolabs).
Cultures were grown in 2xYT media with ampicillin (100 mg/L, Sigma-Aldrich) at 37°C
until they reached an optical density at 600 nm of 0.8. The temperature was reduced to
18°C and cells were induced with 1 mM IPTG (Anatrace) to express protein. Cells were
harvested after 18 hrs expression and pelleted by 5 Krpm centrifugation in a SLC4000
rotor (Sorvall). Cell pellets were stored at -80°C, freeze-thawed and lysed by
microfluidization (Microfluidics, Inc.) in a buffer containing 50 mM Tris pH 8.5, 50 mM
NaCl, 5% glycerol and 2 mM imidazole (Lysis buffer). Lysed cells were centrifuged at
17 krpm to remove cellular debris. The supernatant, filtered through an 0.22-µm filter,
was loaded onto a 5-mL HiTrap Ni-affinity column (GE, Healthcare) equilibrated with
lysis buffer. The column was washed with a buffer of 50 mM Tris pH 8.5, 50 mM NaCl,
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5% glycerol and 10 mM imidazole, and the protein was eluted with the buffer containing
50 mM Tris pH 8.5, 50 mM NaCl, 5% glycerol and 100 mM imidazole.
The eluted fractions were diluted 6-fold with 50 mM Tris pH 8.5 buffer, to
decrease the salt concentration. This protein sample was purified further by anion
exchange chromatography. The partially purified sample was loaded onto a 5-mL HP
High Q column (GE Healthcare) and eluted with a linear NaCl gradient. NS2B-NS3pro
eluted in a buffer of 50 mM Tris pH 8.5, 150 mM NaCl. The eluted protein was incubated
with thrombin during dialysis against 50mM pH 8.5 Tris at 4°C overnight to cleave the
His6 tag. The following day the protein sample was loaded onto 5-mL HiTrap Ni-affinity
column (GE Healthcare) to remove the cleaved His6 tag and the thrombin. The His6-free
protein sample was concentrated to 5 mL and loaded to Hiload Superdex 75 26/60 sizeexclusion column equilibrated with lysis buffer. Samples were eluted with lysis buffer
and fractions were stored at -80°C in the lysis buffer conditions. The identity of the
purified DENV2 NS2B-NS3pro and variants were analyzed by SDS-PAGE to be 99%
pure and ESI-MS was used to confirm the mass of all proteins used.
3.4.3 Kinetics of Cysteine-Substituted Variants. For kinetic measurements of NS2BNS3pro activity, 300 nM-purified NS2B-NS3pro was monitored over the course of 20
min in a NS2B-NS3pro activity assay buffer containing 100 mM Tris pH 9.0. For
substrate titrations, a range of 0-1mM fluorogenic substrate, GRR-AMC, (N-acetyl-GlyArg-Arg-AMC (7-amino-4-methylcoumarin); Ex 365 nm / Em 495 nm; International
peptides) was added to start the reaction. Assays were performed in duplicate at 37°C in
100 µL volumes in 96-well microplate format using a Spectramax M5 spectrophotometric
plate reader (Molecular Devices). Initial velocities versus substrate concentration were fit
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to rectangular hyperbola using GraphPad Prism (Graphpad Software) to determine kinetic
parameters KM and kcat. Enzyme concentrations were determined by monitoring
absorbance at 280 nm using a nano-drop spectrophotometer (Thermo Scientific).
3.4.4 Kinetics of Cysteine-Substituted Variants Under Oxidizing Conditions. 20 µM
of each NS2B-NS3pro double cysteine substitution variant was titrated with the oxidant
cystamine over the range of 1 mM-500 mM. The activity of the NS2B-NS3pro variants
was monitored by cleavage of a fluorogenic substrate as above.
3.4.5 Activity Recovery of Oxidized Proteins. 20 µM of each NS2B-NS3pro double
cysteine substitution variant was incubated with 500 mM cystamine. The excess
cystamine of each mutant was removed by buffer exchange with NAP25 column
(manufacturer). Samples were incubated with reductant (10 mM β-ME) overnight.
Activity was monitored as above.
3.4.6 Mass Spectrometry. NS2B-NS3pro variants in Tris pH 8.5, 50mM NaCl and 5%
glycerol were diluted in 0.1% formic acid to a final concentration of 5 µM in a 200 µl
volume. Samples were applied to a PROTO 300 C4 5 µm column (Higgins Analytical,
Inc.) on an HP1100 HPLC system (Hewlett-Packard) to desalt the protein in line prior to
ionization in the mass spectrometer. Samples were then analyzed on Qstar XL quadrapole
time-of-flight mass spectrometer (Applied Biosystems) with an electrospray ionization
source and positive ion polarity. Scanning was carried out between 600-1400 m/z. A
mass range between 20 kDa and 30 kDa was deconvoluted to obtain corresponding
sample mass. For the I73C/P106C a +178 adduct was observed even in samples that had
never been exposed to cystamine and in the presence of 25 mM β–mecaptoethanol. This
+178 species is a commonly observed(33) and thus was disregarded during our analysis.
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For the V97C / N105C sample, we found that 22% of the protein exposed to cystamine
formed an adduct of +152 Da, suggesting that in 22% of the sample both introduced
cysteines are covalently bound to cysteine. Because 78% of the sample is observed in the
disulfide-formed state, we proceeded with characterization of this sample so that all of
the double cysteine substitution variants could be analyzed at the same cystamine
concentration. For comparison, we also analyzed V97C / N105C in the presence of
cystamine and found no evidence for a cystamine adduct at concentrations that still lead
to full V97C / N105C inhibition.
3.4.7 Quantification of Free Thiols. To monitor the level of disulfide formation, free
thiols remaining in NS2B-NS3pro samples were measured using the quantitative,
colorometric, thiol-reactive reagent (5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB). 60 µM
of NS2B-NS3pro double cysteine substitution variants were buffer exchanged using a
NAP5 column into Tris pH 8.5, 50 mM NaCl and 5% glycerol buffer and then incubated
with 1 mM DTNB Absorbance of each sample was monitored at 412 nm.
3.4.8 Circular Dichroism. Circular dichroism experiments were carried out on a J720
circular dichrometer equipped with Peltier temperature controller (JASCO) at 20°C.
NS2B-NS3pro variants under oxidized or reduced conditions were buffer exchanged by
NAP5 columns (GE Healthcare) into 10 mM pH 8.5-phosphate buffer. The thermal
stability of 5 µM of each protein was assessed by monitoring the circular dichroism
signal at 222 nm as the temperature was increased 1°C/minute over the range from 20 to
90°C.
3.4.9 Size-Exclusion Chromatography. The oligomeric states of the NS2B-NS3pro
variants in oxidized or reduced conditions were analyzed on a Superdex 200 10/300 GL
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gel-filtration column (GE Healthcare). NS2B-NS3pro samples were concentrated in 50
mM NaCl, 5% glycerol and pH 8.5 Tris in a 3K molecular weight cutoff membrane
concentrator (Sartorium Stedim Biotech) to 2 mg/mL. Samples were filtered and loaded
onto the column. Protein was eluted with 50 mM NaCl, 5% glycerol and pH 8.5 Tris
buffer. Peak fractions were identified by monitoring absorbance at 280 nm and the eluted
proteins were analyzed by SDS-PAGE. Molecular weight standards from the gelfiltration calibration kit LMW (GE Healthcare) were run prior to experiment under the
same conditions. A standard curve based on these standards was drawn to determine the
molecular weights of each NS2B-NS3pro variant.
3.4.10 Native Agarose Gel: Native agarose gels were prepared by dissolving 5 g of
agarose in a buffer containing 0.05 M pH 8.5 tris and 20% glycerol. Protein samples
under oxidizing or reducing conditions at 20 µM were mixed with loading buffer (1%
bromophenol blue, 20% glycerol and 50mM pH 8.5 tris) and run on the agarose gel at 85
V for 90 minutes. Gels were stained with a buffer containing 40% methanol, 10% glacial
acetic acid and 0.25% coomassie brilliant blue R-250 for 45 minutes and destained with a
buffer containing 20% methanol and 5% glacial acetic acid overnight.
3.4.11 Intrinsic Tryptophan Fluorescence. 1 µM NS2B-NS3pro variants were
incubated with 500 mM cystamine in Tris pH 8.5, 50 mM NaCl and 5% glycerol buffer
for 1 hr. The samples were buffer exchange to lysis buffer (50mM pH 8.5 Tris, 50mM
NaCl and 5% glycerol) using a NAP25 column (GE Healthcare). The intrinsic tryptophan
fluorescence of 500 nM NS2B-NS3pro variants was measured (Ex. 290/Em. 300-400
nm) on a Quantum Master 30 spectrofluorometer (PTI) as a function of temperature
ranging from 25 to 85°C. Temperature was controlled via circulating water bath.
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Resultant data were fit to a Gaussian hyperbole and the wavelength at the maximum
absorption (λmax) found by calculating the point at which the 1st derivative was equal to 0
(Mathematica, Wolfram Research, Inc).
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CHAPTER IV
FUTURE DIRECTIONS

4.1 Introduction:
Dengue virus protease (NS2B-NS3pro) is a crucial component for dengue virus that
causes dengue fever therefore it has been a drug target for some time. Understanding the
structural and biophysical features that are required for NS2B-NS3pro catalytic activity
can help in developing new strategies for dengue fever treatment. In this dissertation we
have shown that chemical modification of a novel exosite can be sufficient to perturb
NS2B-NS3pro catalytic activity. In addition of that we also found that the flexibility of
NS2B-NS3pro is critical for function of the protease. These findings have paved the way
for other inquiry about the function of the protein. Below I outline some of the central
questions that have been addressed by this thesis and remain to be answered by future
investigators.

4.2 NS2B-NS3pro Binding Partners.
One of the surprising attributes about the NS2B-NS3pro is that it shows such a strikingly
low catalytic turnover in vitro, eight to eleven orders of magnitude slower than some
proteases. We have considered why this exceedingly slow turnover might be observed.
One obvious reason is that it does not need to be any faster as even this slow rate constant
of 1.5 min-1 is sufficient to effectively cleave the Dengue virus polyprotein and allow
infectivity. Another bone fide possibility is that another binding partner, either from
dengue virus or the human host cells that can increases the catalytic activity of the
NS2B-NS3pro in vivo. Constructs for genetically-encoded fluorogenic protease activity
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reporters

(CA-GFP (1, 2) and DVPA-GFP (3)) that have been developed by my

colleagues that allow us to determine the catalytic activity of caspase and NS2B-NS3pro
in cells successfully. Other fluorogenic small-molecule reporters such as the GRR-AMC
reporter used throughout this thesis are also available. By using these types of reporters
the activity of NS2B-NS3pro in cells can be compared with catalytic activity in vitro.
These experiments will let us to test the catalytic activity of NS2B-NS3pro in cells which
is biologically more relevant, and may enable us to identify any physiologically relevant
binding partners. Those binding partners might also prove to be useful targets or cotargets for Dengue directed therapy.

4.3 Link Between NS3 And Apoptosis.
Given that work in our lab centers around the caspase proteases that are involved in the
initiation and execution of apoptotic cell death, reports that NS3 triggers apoptosis(4) are
intriguing to us. We are lead to ponder what the potential mechanism of apoptosis is and
whether there is a link between NS2-NS3pro activity We are particularly curious about
this because it seems so anti-intuitive. If NS3 induces apoptosis, would that not be
detrimental to infectivity (since the cells would be dead)? Alternatively, does NS3 induce
apoptosis later in the viral life cycle enabling viral escape and propagation to other cells.
Caspases are proteases that initiate the programmed cell death in cell, which is called
apoptosis. Overexpression of NS3 induces apoptosis in cell but mechanism is unrevealed.
One of the hypothesizes that we derived from data is that NS3pro may activate caspases
by cleaving the zymogen form. NS2B-NS3pro has cleavage sites in DED domain of
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initiator caspase-8. The effect of cleavage in those sites on caspase-8 by NS2B-NS3pro
activity remains unknown.

4.4 Generality of A125 Binding Site.
In this work we have shown that NS2B-NS3pro from dengue virus type 2 can be
inhibited by compound binding to the A125C residue. The A125 amino acid is conserved
in NS2B-NS3pro from other dengue virus strains (DENV1, DENV3 and DENV3) and
West Nile virus protease. In addition the loops in this region are similar between these
proteases, although they are very different in other trypsin-like proteases (see discussion
in section 2.3). One future direction that should be the outgrowth of the work presenting
in this dissertation is to ask “What would be the effect of compound binding to A125C in
NS2B-NS3pro from other strains and West Nile virus protease?” We also envision that it
should be possible to crystallize NS2B-NS3pro from other strains or/and West Nile virus
protease in ligand bound form, which would provide much needed molecular insight into
the binding and inhibition of NS2B-NS3pro from DENV2.
The observed structures of NS2B-NS3pro of DENV1, DENV2, DENV3 and West
Nile virus are highly related and nearly superimposable (Fig. 33). Therefore we assume
that the same effect that caused inactivation of NS2B-NS3pro from DENV2 upon
compound binding to the A125C site will be observed when a compound binds to A125
residue of NS2B-NS3pro from other strains. Exploring that may lead to finding a global
exosite in NS2B-NS3pro from all of the proteases in the flavivirus family.
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Figure 33. The structures of NS2B-NS3pro from DENV1, DENV2 and West Nile
virus are nearly super-imposable in the NS3 domain

4.5 Conformational Equilibrium
Together the work in this dissertation and elsewhere has convincingly shown that there is
equilibrium between open (yellow) and closed (green) conformations of NS2B-NS3pro
Fig. 34) and NS2B adopts the closed conformation when NS2B-NS3pro is active. Based
on the work presented in this dissertation, we conclude that shifting equilibrium toward to
open conformation can causes inhibition of NS2B-NS3pro. The work presented here
suggests that a fruitful line of future inquiry would be to seek to understand what factors
affect the equilibrium between closed and open conformations of NS2B-NS3pro in
solution.
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The T111C, L115C and W83C (Fig. 35) variants were found to be inactive (see
Chapter 3). Using EPR labeling methods one can assess a possible shift in equilibrium of
those variant which may be an explanation for their inhibition.

Figure 34. NS2B (blue) region of NS2B-NS3 undergoes large conformational
rearrangements upon substrate binding to active site.
Since NS2B-NS3pro do not have native cysteine in their structure any part of enzyme can
be labeled by MTSSL spin label specifically in order to study the dynamics in NS2B
region, so these experiments are greatly facilitated.
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Figure 35. The location of T111, L115 and W83 are shown relative to active site.
Although these sites are remote to active site we have seen full inactivation of
NS2B-NS3pro when we replace them to cysteine.
4.6 Conclusion
In conclusion, in this dissertation we have shown that NS2B-NS3pro from dengue virus
type 2 can be inactivated by chemical modification of an exosite located between
loop120 and loop150. We posit that other related proteins in this family should also be
susceptible to inactivation by the same mechanism. Another intersesting finding of this
dissertation is that the catalytic efficiency of that enzyme is mostly dependent on internal
flexibility. Constriction of that flexibility is shown to be enough for inhibition of NS2BNS3pro.
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APPENDIX A
EXPRESSION AND PURIFICATION OF NS2B-NS3PRO WILD TYPE AND A125C
VARIANTS FOR CRYSTALLIZATION
A.1 Introduction
In order to achieve crystals, we found it necessary to develop a new purification strategy
for Dengue virus protease (NS2B-NS3pro). Thus in this thesis NS2B-NS3pro has been
purified in different way that can be found elsewhere. We have adapted a method that has
been used by a Novartis research group that was able to crystallize the apo form of
dengue virus protease (2FOM). We have followed the procedure that is detailed below
and were able to crystallize and solve crystal structure of NS2B-NS3pro from dengue
virus protease type 2.
A.2 Results
The purity level that we always got was quality enough to crystallize the NS2B-NS3pro.
Crystals diffracted up to 1.46 Å suggesting that the protein was of high purity.
A.3 Expression and Purification NS2B-NS3pro Wild Type And A125C Variant
A.3.1 Cell Growth:
1- Grow 5ml overnight culture in LB from a single colony of BL21 (DE3) bacterial
cells that is transformed with the NS2B-NS3pro DVP2 plasmid. The plasmids
used are pET15b for WT NS2B-NS3pro and A125C NS2B-NS3pro. These
plasmids have been archive in the Hardy lab DNA archive in box IV in slots 78
and 79.
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2- Dilute 1 mL of the overnight cell growth in 2L 2xYT media. Grow cells at 37°C
until OD600 reaches 0.8.
3- Induce cells for protein expression at OD600 of 0.8 by addition of IPTG (500 µM
final concentration) for 20 hours at 18°C.
4- Harvest cells by centrifugation (5000 rpm for 10 minutes) and store cell paste at
-80°C.

A.3.2 Purification
1st step NS2B-NS3pro Ni Affinity Column Purification and Thrombin Digestion.
Buffers
Lysis Buffer: 50 mM NaCl, 20 mM pH 8.5 Tris, 5% (v/v) Glycerol, 2 mM Imidazole
Wash buffer: 50 mM NaCl, 20 mM pH 8.5 Tris, 5 % (v/v) Glycerol, 20 mM Imidazole
Elution Buffer: 50 mM NaCl, 20 mM pH 8.5 Tris, 5 % (v/v) Glycerol, 120 mM
Imidazole
1- Cell paste (18 g) is resuspended in 100 mL lysis buffer.
2- Cells are lysed by microfludizer and clarified with centrifugation (17 K rpm for 45
minutes).
3- Supernatant is filtered by 0.22 µm filter and loaded onto Ni column (Ni-Chelating
HP column, GE, 5ml) that has been equilibrated with lysis buffer.
4- Column is washed with wash buffer for 10 CV (50 mL). NS2B-NS3pro is eluted
with elution buffer.
5- Typical yield is 20 mL of ~5 mg/ml total protein after the Ni-affinity column.
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Figure A1: SDS-PAGE gel was run after Ni-NTA purification.DVP2 is pionted by
arrow.
2nd step NS2B-NS3pro Hiq (Ion Exchange HP, GE, 5ml) Purification.
1-Buffer A
50mM pH: 8.5 tris, 30mM NaCl
2-Buffer B
50mM pH: 8.5 Tris, 300 mM NaCl
Experimental design:
1- HiQ (ion exchange HP, GE, 5ml) column was equilibrated with Buffer A.
2- Ni-Column elution fraction was diluted by 6-fold with Buffer A and loaded onto a
HiQ column pre-equilibrated in 100% Buffer A.
3- NS2B-NS3pro eluted with a linear NaCl gradient (0% Buffer B to 60% Buffer B
during a 50 CV gradient).
4- HiQ peak fractions were run on SDS gel to validate the presence and purity of
NS2B-NS3pro.
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5- Fractions from the anion exchange chromatography purification step were pooled
and incubated with 100 U (unit) thrombin at 4°C while dialyzing in 50mM pH:
8.5 Tris overnight in order to cleave the N-terminal His6 tag.

Figure A2: SDS-PAGE gel was run after HiQ (anion exchange) purification. NS2BNS3pro is indicated by the arrow.
3rd step 2nd Ni Purification.
In order to seaparte the His6-tag-cleaved NS2B-NS3pro protein fractions from the
cleaved His-tag peptide and His tag attached NS2B-NS3pro, we have run a 2nd Ni column
purification.

Experimental design:
1- Ni column equilibrated with wash buffer as in Step 1 above.
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2- The NS2B-NS3pro sample from the overnight dialysis was loaded onto the Ni
column.
3- Flow-through was collected. Column was washed with wash buffer for 2 CV (10
ml) and the flow through collected into the same tube.

4th Step
Size exclusion chromatography purification using a Superdex75 Hiload 26/60 size
exclusion column, GE Healthcare.
SEC buffer
50mM pH: 8.5 tris, 50mM NaCl, 5% (v/v) glycerol
Experimental design:
1- NS2B-NS3pro protein (fractions from 2nd Ni-purification) were concentrated to 5
ml. Usually we get 4 mg/ml of 5 ml total sample.
2- The 5 ml NS2B-NS3pro sample was loaded onto the size exclusion column (SEC)
that is equilibrated with SEC buffer.
3- NS2B-NS3pro eluted at 154.68 mL (61.87 min) with 2.5 ml/minutes flow rate.
4- Peak fractions were run on the SDS gel and the purest fractions determined.
5- Pure protein fractions pooled and flash-frozen. Frozen aliquots were stored at
-80°C. They stay fully active up to 2 months in freezing conditions.
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Figure A3: SDS-PAGE gel was run after SEC (sixe exclusion chromatography)
purification. NS2B-NS3pro is indicated by the arrow.

A.4 Activity Assays Using Peptide Substrates
In order to measure the kinetic parameters of NS2B-NS3pro, 500 nM freshly
purified protein was assayed in 0.1 M Tris pH 9 for 20 minutes.
For substrate titrations, a range of 0-1 mM fluorogenic substrate that was GRRAMC, (N-acetyl-Gly-Arg-Arg-AMC (7-amino-4-methylcoumarin), International peptide)
Ex. 365 nm / Em. 495 nm added to start the reaction. Assays were done in duplicate at
37°C in 100 µL volumes in 96-well microplate format by using a Molecular Devices
Spectramax M5 spectrophotometer. Vo versus substrate concentration was fit to a
hyperbola using GraphPad Prism (Graphpad Software) to determine kinetic parameters
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Km and kcat. Enzyme concentrations were determined by nano-drop instrument simply by
looking AU280 absorbance.

0.8

Vo(rfu/se)

0.6

0.4

0.2

0.0
0

200

400

600

800

1000

GRR(µM)

Figure A4: Michael-Menten plot of WT NS2B-NS3pro was plotted to determine the
kinetic parameters such as kcat and KM.
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A.5 NS2B-NS3pro Wild Type Crystallization and Data Collection
Purified NS2B-NS3pro was concentrated to 40 mg/mL by Amicon Ultrafree 5K NMWL
membrane concentrators (Millipore Inc.) and filtered with a 0.22 µm filter prior to
crystallization. The reported crystallization conditions were 0.1 M pH 5.5 Acetic acid, 40
% PEG 200 (1). By using making fractional dilutions from related conditions as shown in
the four corners of a tray (Table A1), 24 conditions that are close to reported conditions
were
. Table A1: 24 well tray has been used to grow the NS2B-NS3pro crystal. Each well
contains a unique but close related condition.
1
2
3
4
5
6
A
100 % A1 75 % A1
50 % A1
25 % A1
10 % A1
0 % A1
0 % A6 25 % A6
50 % A6
75 % A6
90 % A6
100 % A6
B

C

H

50 % A1
0 % A6
50 % D1
0 % D6
80 % A1
0 % A6
20 % D1
0 % D6
100 % D1
0 % D6

37.5 % A1
12.5 % A6
37.5 % D1
12.5 % D6
60 % A1
20 % A6
15 % D1
5 % D6
75 % D1
25 % D6

25 % A1
25 % A6
25 % D1
25 % D6
40 % A1
40 % A6
10 % D1
10 % D6
50 % D1
50 % D6

12.5 % A1
37.5 % A6
12.5 % D1
37.5 % D6
35 % A1
40 % A6
10 % D1
15 % D6
25 % D1
75 % D6

5 % A1
45 % A6
5 % D1
45 % D6
8 % A1
72 % A6
2 % D1
18 % D6
10 % D1
90 % D6

0 % A1
50 % A6
0 % D1
50 % D6
0 % A1
40 % A6
0 % D1
60 % D6
0 % D1
100 % D6

prepared (Table 1). NS2B-NS3pro crystals appeared in two days and were frozen after
one week. Since 40% PEG200 was sufficient to prevent ice crystals from forming during
freezing, no additional cryo-protectant was not used
Four corners buffers:
Buffer A1: 0.1 M Acetic acid pH: 5.5 + 45 % PEG 200, Buffer A6: 0.1 M Acetic acid
pH: 5.5 + 35 % PEG 200, Buffer D1: 0.1 M Acetic acid pH: 5.3 + 45 % PEG 200, Buffer
D6: 0.1 M Acetic acid pH: 5.3 + 35 % PEG 200
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Dengue virus protease crystals;

Figure A5: NS2B-NS3pro crsytals. They were grown in reported conditions that
has been found by Novartis research group (left panel). Diffraction pattern was
shown in one of the image that has been taken during full data set collection (right
panel). Scale bar shows 200 µm length.

A.5.1 Structure Determination.
Diffraction data for dengue virus protease wild type were processed in the orthorhombic
space group C2221 with CCP4i (Bailey 1993). The search model used for molecular
replacement was a NS2B-NS3pro from dengue virus protease type 2 (PDB ID 2FOM, 1.5
Å resolution) by using Phaser (McCoy et al. 2007).
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Figure A6. Z-score and initial R-factor after phaser. It indicates a successful MR
(molecular replacement) solution.
The solution (Fig. A6) was successful and gave one monomer in the asymmetric unit.
Model was built into the electron density based on experimental data by iterative rounds
of model building in Coot (Emsley and Cowtan 2004) and NCS restrained refinement
using CCP4i (Bailey1993). The structure was refined using Refmac (Murshudov, Vagin,
and Dodson 1997) and TLS to a final R/Rfree of 20.3%/22.3% and was validated by
Procheck (Laskowski et al. 1993) using CCP4i.
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A.6 Results

Figure A7: The structure of NS2B-NS3pro. It has been solved in this thesis is shown
superimposed with reported known NS2B-NS3pro structure (2FOM).The only diffrences
between the structure solved as part of this thesis (in green) and the reported structure
(yellow) was the conformation of 120s loop.
The structure we have solved showed that the loop-120 is flexible but the rest of
sutructure including active site traid wwas superimposed with prviously reported NS2BNS3pro structure (2FOM).
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APPENDIX B
EPR STUDIES ON NS2B MOVEMENTS
B.1 Background
Site-directed spin labeling (SDSL) electron paramagnetic resonance (EPR) is a wellestablished method that provides structural information about proteins (3). The SDSL
technique involves introducing a cysteine at the site of interest, and that site is labeled
with an EPR detectable probe spin label such as (S-(2,2,5,5-tetramethyl-2,5-dihydro-1Hpyrrol-3-yl)methyl methanesulfonothioate (MTSL) (Fig. B1). The EPR detectable probe
has a different spectroscopic signature depending on its environment.

Simply by

analyzing the EPR spectra one can get information about flexibility, the nature of protein,
secondary structure content in the region that the EPR probe is attached to, protein
interactions, membrane depth, or distance between two residues (4) that are labeled with
the EPR probe (Fig. B1).
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Figure B1. MTSL EPR label covalently and specifically attaches the cysteine that is
introduced in the region of interest. Figure reprinted from (5).

B.1.1 Motion
The EPR spectra is sensitive to the motion of the label. EPR line shape can be used to
acquire information about the mobility of the label, which directly reflects the mobility of
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site to which the label is attached. Different spectroscopic signatures, which vary based
on the flexibility of the regions that to which the EPR probe is attached, are shown in the
Fig. B2.

mI +1

0

−1

A

B

C

D

Figure B2. Observed EPR spectra vary based on the motion of site that is labeled with
the EPR probe. (A) is dilute free MTSL label, (B) MTS is bound to a 15- residue peptide,
(C) the peptide is folded into an α-helix, and (D) the spin labeled-peptide is frozen.
Figure reprinted from (5).
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B.1.2 Distances
With the SDSL technique one can also measure the distance between two spin labels in
the same protein or in different proteins. By measuring the distance between two labels,
information about functional protein dynamics and structure can be provided. Distance
measurements are based on observing the effect of magnetic dipolar interactions between
two unpaired electrons in an EPR probe. In the range of 8-20 Å, interactions between
EPR labels give distance-dependent line broadening. By computing the spectra, the
distance between two labels can be determined.

Figure B3. Spin-spin broadening. The grey line represents the sum of two single labels,
while the black line shows the line broadening that results from dipolar interactions
between two labels. Figure reprinted from (5).
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B.2 Introduction
In this thesis, we have shown that the NS2B region of NS2B-NS3pro is mobile and that
there is equilibrium between the closed and open conformations observed in recent
structural studies. NMR data suggests that NS2B is predominantly in the closed
conformation when substrate is not bound to the active site (1) while x-ray structures
show the open structure is dominant (2), although to date there has been no DENV2
NS2B-NS3pro structure in the presence of substrate. Despite those controversies, data
from NMR and x-ray studies are in agreement about the flexibility of NS2B and presence
of equilibrium between open and closed states. In order to interrogate the equilibrium
between open and closed states we designed an EPR experiment. In the EPR experiment,
particular residues were replaced by cysteine and labeled with EPR-active probe MTSL.
It was our expectation that the two MTSL labels would show a strong coupling effect
when they are close to each other, such as at a 5Å distance. The coupling effect is not
prominent when MTSL probes are distant, such as 30 Å. Although we were able to
prepare single- and double-cysteine substituted NS2B-NS3pro, and could measure EPR
spectra, the EPR data were not conclusive enough to make a model about equilibrium
between closed and open conformations. Nevertheless these data provide preliminary
evidence that this kind of EPR approach could be used to interrogate the equilibrium of
conformational states.
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B.3 Material and Methods
B.3.1 Double Mutant Design;
The crystal structure of apo DENV2 NS2B-NS3pro (2FOM) and substrate bound
structure of DVP3 NS2B-NS3pro (3U1I) were visually inspected to design cysteine pairs
that are close in 2FOM structure and far apart in 3U1I structure. Initially E90C/G103C
double mutant was designed. The distance between these two residues is 5Å in 2FOM
structure while becomes 30Å in the 3U1I structure. Cysteines were introduced by
quikchange mutagenesis.

Figure B4: The structure of DENV2 NS2B-NS3pro (2FOM, magenta/yellow) and
DENV3 NS2B-NS3pro (3U1I, magenta/green) substrate bound structure. NS2B region is
shown in magenta while NS3pro core in green or yellow. NS2B is in two distinct
conformations in 2FOM and 3U1I.
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B.3.2 Double Cysteine Variant Purifications
NS2B-NS3pro expression constructs were transformed into the BL21 (DE3) T7 Express
strain of E. coli (New England Biolabs). Cultures were grown in 2xYT media with
ampicillin (100 mg/L, Sigma-Aldrich) at 37°C until they reached an optical density at
600 nm of 0.8. The temperature was reduced to 18°C and cells were induced with 1 mM
IPTG (Anatrace) to express protein. Cells were harvested after 18 hrs expression and
pelleted by 5 krpm centrifugation in a SLC4000 rotor (Sorvall). Cell pellets were stored
at -80°C, freeze-thawed and lysed by microfluidizer (Microfluidics, Inc.) in a buffer
containing 50 mM Tris pH 8.5, 50 mM NaCl, 5% glycerol and 2 mM imidazole (Lysis
buffer). Lysed cells were centrifuged at 17 krpm to remove cellular debris. The
supernatant filtered in an 0.22-µm filter was loaded onto a 5-mL HiTrap Ni-affinity
column (GE, Healthcare) equilibrated with lysis buffer. The column was washed with a
buffer of 50 mM Tris pH 8.5, 50 mM NaCl, 5% glycerol and 10 mM imidazole, and the
protein was eluted with the buffer containing 50 mM Tris pH 8.5, 50 mM NaCl, 5%
glycerol and 100 mM imidazole.
The eluted fractions were diluted 6-fold with 50 mM Tris pH 8.5 buffer, to
decrease the salt concentration. This protein sample was purified further by anion
exchange chromatography. The partially purified sample was loaded onto a 5-mL HP
High Q column (GE Healthcare) and eluted with a linear NaCl gradient. NS2B-NS3pro
eluted in a buffer of 50 mM Tris pH 8.5, 150 mM NaCl. The eluted protein was stored in
-80°C.

%&)!

!
B.3.3 Double Cysteine Variants Labeling With MTSL EPR Probe.
Purified 100 µM of E90C/P106C was labeled with MTSL EPR active probe by
incubating the sample with 2 mM of EPR active MTSL probe overnight in 25°C. After
incubation, samples were loaded onto a NAP5 column in order to remove excess,
unbound MTSL label. The NS2B-NS3pro NAP5 column fractions were concentrated to
200 µM in 50 mM pH 8.5 tris buffer for the EPR measurement.
B.4 EPR Experiment
Dr Peng Wu, an EPR expert and I, put 50 µL of 200 µM labeled NS2B-NS3pro samples
in quartz capillary tubes and the E-500-10/12 electron paramagnetic resonance
spectrometer system (Bruker corp.) used to measure electron magnetic resonance. In
order to increase the signal over noise ratio, two hundreds measurements were averaged.
B.4.1 Results

Figure B5: EPR spectrum of the MTSL-labelled E90C/G103C and E90C cysteine
substitution variants.
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The effect of electron coupling on line broading (Fig. B3) were not observed. Thus data
we have collected do not show the expected interactions between the two labels that were
attached to E90C/G103C sites, that look like they should be within electron coupling
range, according to the crystal structure of unliganded NS2B-NS3pro (2FOM).
From these data we conclude that either E90 and G103 sites were not proparly labeled or
the distance between two residues are not in the range that is shown in the crystal
structue.Data also indicate that the E90 region has a high motility which is an expected
result according available crystal structure of NS2B-NS3pro. A relative broadining that is
observed in the EPR spectra of E90C/G103C EPR indictaes the less mobile component
correspods to G103C (Fig B2-C). In the crystal structure the G103 residue is located on
the surface of the NS3 part of NS2B-NS3 proenzyme that does not show any significant
mobility according the available structural information. Another reason for not observing
the line broadening might be that E90C/G103C sample might be a mixture of singly
labeled G103C and E90C, due to low labeling efficiency. !
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